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Abstract: 
 
Background: 
The effects of vitamin D on fracture, falls and bone mineral density (BMD) are uncertain, 
particularly for higher vitamin D doses. 
 
Methods: 
Random-effects meta-analyses and trial sequential analyses (TSA) of randomised controlled 
trials (RCTs) of vitamin D (in which treatment arms only differ by vitamin D) in adults with 
total fracture, hip fracture, falls, or BMD at the lumbar spine, total hip, femoral neck, total 
body or forearm as outcomes identified from Pubmed, Embase, Cochrane CENTRAL, and 
two clinical trial databases, last search Feb 2018.  
 
Findings: 
81 RCTs reported fracture (n=42), falls (n=37), or BMD (n=41). In pooled analyses, vitamin 
D had no effect on total fracture [36 trials, n=44790, RR 1.00 (95%CI 0.94-1.07)], hip 
fracture [(20 trials, n=36655, RR 1.11 (0.97-1.26)], or falls [37 trials, n=34144, RR 0.97 
(0.93-1.02)]. Results were similar in RCTs of higher vs lower dose vitamin D and in 
subgroup analyses of RCTs using doses >800 IU/d. In pooled analyses, there were no 
clinically relevant between-group differences in BMD at any site (range -0.16% to 0.76% 
over 1-5y).  
 
The effect estimate in the TSAs lay within the futility boundary at a threshold of 7.5% risk 
reduction for total fracture and falls, lay between the futility boundary and the inferior 
boundary at a 15% risk reduction for hip fracture, and lay within the futility boundary at 
thresholds of 0.5% for total hip, forearm, and total body BMD, and 1.0% for lumbar spine 
and femoral neck, providing reliable evidence that vitamin D does not alter these outcomes 
by these amounts.  
 
Interpretation 
Vitamin D supplementation does not prevent fractures or falls, or have meaningful effects on 
BMD. There were no differences between the effects of higher and lower doses of vitamin D. 
 
Funding: Health Research Council of New Zealand. 
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Background:  
Vitamin D supplements have long been recommended for older people to treat or prevent 
osteoporosis,1 with some early evidence suggesting benefits for musculoskeletal health, 
including increasing bone mineral density (BMD), and preventing falls and fractures.2 
However, later systematic reviews have reported no effect of vitamin D supplementation on 
BMD,3 falls,4-7 or fractures.7-10 Trial sequential analyses for the hypothesis of a 15% relative 
risk reduction in falls or fractures showed that conducting further trials of vitamin D with or 
without calcium supplementation that are similar to the existing trials is unlikely to alter the 
conclusion of the recent systematic reviews.6,9 However, correspondents questioned the 
utility of this efficacy threshold and also suggested that inadequate vitamin D doses might 
explain these null results,11,12 although some randomised controlled trials (RCTs) have 
reported increased risk of falls or fractures with high dose intermittent vitamin D.13-15 Since 
the last major systematic reviews of vitamin D on musculoskeletal health were published in 
2012-14, 3-10 45 RCTs of vitamin D monotherapy (n=20,131) have reported on BMD, falls 
and fractures, increasing the number of trial participants with these outcomes by 40-85%. 
Most newer trials have also used substantially higher doses of vitamin D than earlier trials. 
Consequently, the currently available set of RCTs has much greater power for meta-analysis 
and trial-sequential analysis, and allows a detailed exploration of potentially important 
clinical factors in subgroup analyses, including comparisons of higher and lower doses of 
vitamin D. Therefore, a comprehensive update of previous systematic reviews, meta-
analyses, and trial-sequential analyses, that includes the important clinical and major 
surrogate endpoints, is warranted. An advantage of assessing these outcomes concurrently is 
that it is possible that an effect may be found for some endpoints whereas no effect is found 
for others, which might have clinical and biological relevance. Trial-sequential analyses of 
vitamin D and BMD have also not been previously reported. 
 
Previously, vitamin D supplements have often been co-administered with calcium 
supplements. Recent systematic reviews have suggested that the evidence for benefits of 
calcium supplements, with or without vitamin D, in preventing fractures is only weak and 
inconsistent,10,16 with any effect on BMD or fracture likely very small and of doubtful clinical 
relevance.10,16,17 In addition, uncommon but important side-effects of calcium supplements18-
21 have been identified contributing to an unfavourable risk-benefit profile. No large trials of 
co-administered calcium and vitamin D supplements have become available with fracture or 
falls as the primary endpoint since the previous systematic reviews.  
 
We therefore have undertaken a systematic review, meta-analyses and trial sequential 
analyses of RCTs in adults of vitamin D supplements on the clinical musculoskeletal 
outcomes of fractures and falls and the commonly used surrogate endpoint of BMD. To align 
with the recent findings on calcium supplements, and the recent design of vitamin D RCTs, 
we have focused on RCTs that have used vitamin D as monotherapy, and included RCTs that 
compared higher doses of vitamin D with lower doses.  
 
Methods: 
Literature search 
The PRISMA guidelines for development of protocols22 and reporting of systematic reviews 
and meta-analyses were followed.23 We used our literature searches for previous meta-
analyses3,6,8,9,16,17 as the starting point. For the most recent of these searches, we searched 
Pubmed in December 2015 for RCTs and recent systematic reviews of vitamin D in adults. 
We identified all studies from this search and our previous meta-analyses with fracture, falls, 
or bone density as an outcome. We then searched Pubmed, Embase, and Cochrane 
Page 4 of 65 
 
CENTRAL in Sept 2017 and Feb 2018 using the term “vitamin D” and keywords shown in 
Appendix e1 for publications since 2015. We also searched two clinical trials databases, 
ClinicalTrials.gov and the WHO clinical trials portal, for completed and ongoing trials using 
vitamin D as the search term. The full text of the search is described in Appendix e1. 
 
Study selection 
We included RCTs in adults (>18y) comparing vitamin D supplements with untreated 
controls, placebo or lower dose vitamin D supplements. Trials with multiple interventions (eg 
co-administered calcium and vitamin D) were eligible provided that the study arms differed 
only by the use of vitamin D. We included quasi-randomized and open-label trials but 
excluded trials of hydroxylated vitamin D analogues. RCTs in cohorts with conditions likely 
to impact on bone turnover or cohorts selected for specific diseases (for example: primary 
hyperparathyroidism, renal or hepatic disease) were included but analysed separately in the 
initial analyses. We included RCTs with outcome data on total or hip fracture, falls, or BMD 
measured using dual energy x-ray absorptiometry (DXA) at the lumbar spine, total hip, 
femoral neck, total body, or forearm. Trials reporting BMD using other techniques were 
excluded. Cluster RCTs were included. One author (MB) screened titles and abstracts, two 
authors (MB, AA) reviewed listings on trial registries, and two authors independently (MB, 
AG) reviewed the full-text of potentially relevant studies. Studies included in previous meta-
analyses but excluded from these meta-analyses are shown in Appendix e2. The flow of 
articles is shown in Appendix e3. 
 
Data Extraction:  
Data on participant characteristics, study design, interventions, outcomes, funding sources 
and conflicts of interest were extracted by one author (MB) and checked by a second author 
(AG). Where data were presented only in figures, we used digital callipers to extract data. 
Where data for falls but not fractures were reported, we emailed the authors requesting any 
data on fractures (Appendix e2). The risk of bias of eligible RCTs was independently 
assessed by two authors (MB, AG) following the approach in the Cochrane handbook.24 
Discrepancies in author assessments were resolved by discussion.  
 
Outcomes: 
The co-primary endpoints were participants with ≥1 fracture, ≥1 hip fracture, or ≥1 fall. 
Where multiple classifications of total fracture were reported, we used the largest number of 
participants with any fracture, non-vertebral fracture or osteoporotic fracture. The secondary 
endpoints were the percentage change in BMD from baseline at lumbar spine, total hip, 
femoral neck, total body, and forearm.  
 
Data Analysis and Statistics:  
We grouped RCTs comparing vitamin D supplementation with controls together with RCTs 
comparing vitamin D plus agent with the agent alone (termed vitamin D vs controls). Several 
trials had multiple vitamin D treatment arms. If there was a control group, we pooled the 
vitamin D treatment arms and compared the pooled results with the controls. If there was no 
control group, we pooled treatment arms in which the vitamin D dose was ≥800IU/d (‘higher’ 
dose), and compared the results to the pooled result of treatment arms where the dose was 
<800IU/d (‘lower’ dose). In subgroup analyses, we used relevant individual treatment arms 
for each trial. 
 
For fractures and falls, we initially analysed RCTs conducted in unselected populations and 
selected populations separately, and also analysed RCTs comparing vitamin D with controls 
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and RCTs comparing different doses of vitamin D separately. If the results from the different 
groups of trials were similar, then the RCTs were pooled in subsequent analyses. For BMD, 
the same approach was undertaken, but the further variable of study duration was also 
analysed. BMD RCTs were categorised into 3 groups by duration: ‘1 year’- duration <1.5 
years; ‘2 years’- duration ≥1.5 years and ≤2.5 years; and ‘3+ years’. 
 
Data for fractures and falls were compared using relative risks with an intention-to-treat 
analysis using all available data and the number of participants randomised to the treatment 
for each group. BMD data were compared using the weighted difference in means. For all 
analyses, data were pooled using random-effects models, heterogeneity was evaluated using 
the I2 statistic (I2 >50% was considered significant heterogeneity), and systematic bias was 
assessed using Funnel Plots and Egger’s test (Comprehensive Meta-Analysis, version 2, 
Biostat, Englewood New Jersey, USA). All tests were two-tailed and p-values <0.05 were 
considered statistically significant. The sample size of cluster RCTs was adjusted in 
accordance with the Cochrane Handbook.24 Raw BMD and absolute change from baseline 
were converted to percentage change using the methods described in the Cochrane 
Handbook.24 For studies that reported mean BMD but not a measure of spread, we imputed 
the standard deviation using the median site-, duration-, and treatment group-specific 
standard deviation from other included studies, and separately analysed these studies to 
determine the impact of this approach.  
 
Trial sequential analysis25,26 was carried out for each outcome (TSA Viewer, version 0.9.5.10 
Beta; www.ctu.dk/tsa). This is a type of cumulative meta-analysis that reduces the risk of 
false-positive results from repetitive statistical testing and reports the information size, an 
estimate of the optimum sample size for statistical inference, and estimates of treatment 
effects and thresholds for statistical significance and futility taking into account multiple 
statistical tests.25,26 For fractures and falls, we initially used a 15% relative risk reduction 
threshold, as in our previous publications,6,9 and in further analyses used progressively 
smaller thresholds until the optimum sample size exceeded the actual sample size. For BMD, 
we initially used a threshold of a 3% increase, representing the approximate average BMD 
loss of a late post-menopausal women over 2-4 years, and then progressively smaller 
thresholds. To accommodate heterogeneity between trial results, we used the larger of 15% or 
the calculated heterogeneity from the meta-analysis of included RCTs in the trial sequential 
analysis.  
 
Prespecified subgroup analyses were undertaken testing for interactions between the effects 
of vitamin D supplementation on fractures, falls, and BMD for the following factors, each of 
which is frequently invoked as a possible modifier of the effects of vitamin D: age <65 vs 
≥65y, BMI <30 vs ≥30 kg/m2, baseline 25-hydroxyvitamin D (25OHD) <25 vs ≥25 nmol/L, 
<50 vs ≥50 nmol/L, <75 vs ≥75 nmol/L; achieved 25OHD ≥50 vs <50 nmol/L, ≥75 vs <75 
nmol/L, dose of vitamin D ≤800 IU/day vs >800 IU/day; intermittent vs daily dosing; trials at 
overall low risk of bias vs trials at moderate or high risk of bias; trial duration ≤1y vs >1y; 
trial size ≤200 vs >200 participants; use of co-administered calcium vs no calcium; and 
location- residential care vs community-dwelling. For intermittent doses where the daily 
equivalent dose is approximately 800 IU/day (eg 300,000 IU/year), we included these trials in 
the ≤800 IU/day group. All such trials had an equivalent daily dose of <1000 IU. 
 
Role of the funding source 
The funders had no role in the study design; collection, analysis, and interpretation of the 
data; writing of the report; and in the decision to submit the paper for publication. All authors 
Page 6 of 65 
 
had access to raw data, which are provided in the Appendix. The corresponding author had 
the final responsibility to submit for publication.  
 
Results: 
Baseline characteristics and outcome data 
We identified 81 eligible RCTs of vitamin D supplements13-15,27-107 that reported fracture 
(n=42), falls (n=37), or BMD (n=41) as an outcome (Appendix e3). The study design and 
selected baseline characteristics of the RCTs are shown in Appendix e4 and e5 and 
summarised in Table 1. The majority of RCTs studied vitamin D as monotherapy, in 
unselected populations of community-dwelling women aged >65 years, using daily doses of 
>800 IU/day and had a duration of ≤1 year. The majority of trials (57%) were carried out in 
populations with mean 25OHD <50 nmol/L but only 4 were carried out in populations with 
mean 25OHD <25 nmol/L. 91% of trials reported achieved 25OHD ≥50 nmol/L and 58% 
achieved 25OHD ≥75 nmol/L. Appendix e6 shows our assessment of risk of bias, and e7 
conflicts of interest and funding source. Nine (21%) RCTs were considered at low risk of bias 
for fractures, 22 (59%) low risk for falls, and 29 (71%) low risk for BMD.  
 
Appendix e8 shows the outcome data for each study for each endpoint. 
 
Co-primary endpoints: fractures and falls 
Figures 1-3 show the results of the meta-analyses for total fracture, hip fracture, and falls by 
study design and population. For all 3 outcomes, there was no statistically significant 
interaction for results between RCTs with different study designs (vitamin D vs controls, 
higher vs lower dose vitamin D) in unselected populations, or between trials in selected and 
unselected populations. Therefore, we pooled all the RCTs, finding no effect of vitamin D 
supplementation on total fracture [36 trials, n=44790, RR 1.00 (95%CI 0.93-1.07)], hip 
fracture [(20 trials, n=36655, RR 1.11 (0.97-1.26)], or falls [37 trials, n=34144, RR 0.97 
(0.93-1.02)]. Using Egger’s regression model and visual inspection of funnel plots, data 
appeared skewed toward a reduction in events with vitamin D supplementation for all 3 
outcomes, largely due to an excess of small-medium size studies with positive effects on the 
outcomes.  
 
Figures 1-3 and Table 2 show the results of the trial sequential analyses. For total fracture and 
falls, the effect estimate lay within the futility boundary for risk reductions of 15%, 10%, 
7.5% and 5% (total fracture only) providing reliable evidence that vitamin D supplementation 
does not reduce fractures and falls by these amounts. For hip fracture, at a 15% risk 
reduction, the effect estimate lay between the futility boundary and the inferior boundary, 
meaning there is reliable evidence that vitamin D supplementation does not reduce hip 
fractures by this amount, but uncertainty remains as to whether it might increase hip 
fractures.  
 
Secondary endpoints: bone density 
Figures 4-6, Appendix e9-e11 show the results of the meta-analyses for BMD by site. First, 
we compared the results of trials with missing measures of spread and imputed standard 
deviations to the other trials, by duration, design and population. Appendix e9 shows that 
generally there was little difference between results, and therefore we included the trials with 
imputed standard deviations in subsequent analyses. Next, we compared the results of trials 
by duration, study design, and population type. Appendix e9 shows that for all combinations 
of these factors, there was very little difference in results between the subgroups, and 
therefore we pooled the trials with differing study designs (vitamin D vs controls, higher vs 
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lower dose vitamin D) and those in selected and unselected populations. Because there were 
only small differences by trial duration, we also pooled all the trials using the final time point 
data only for each trial. Figures 4-6, Appendix e10-11 show the between-group differences in 
BMD by site, by trial duration, and the pooled analyses using the final time point. Between-
group differences in BMD did not consistently increase with increasing trial duration at any 
site, and in the pooled analyses using the final time point the between-group differences were 
0.25%, 0.34%, 1.12%, -0.16%, and 0.13% at the lumbar spine, total hip, femoral neck, 
forearm, and total body. Of note, at the femoral neck one RCT107 reported a between-group 
difference of 10.6% (95%CI 9.0-12.3) after 1y which was a clear outlier and had a 
disproportionate effect on the pooled result. We excluded this trial107from subsequent 
analyses, and after its exclusion, the between-group difference at the femoral neck was 0.76% 
(Figure 6). Using Egger’s regression model and visual inspection of funnel plots, data 
appeared skewed toward increased BMD with vitamin D supplementation for all sites except 
the forearm, again largely due to an excess of small studies with positive effects on BMD. All 
subsequent trial sequential analyses and subgroup analyses were performed using the final 
time point data only for each trial. 
 
Table 2, Figures 4-6, Appendix e10-11, show the results of the trial sequential analyses. For 
the total hip, forearm, and total body sites the effect estimate lay within the futility boundary 
for a between-group difference of 0.5% (or more), and at the lumbar spine and femoral neck 
the effect estimate lay within the futility boundary for a difference of 1.0% but above the 
superior boundary for a difference of 0.5%.   
 
Subgroup analyses  
Reported analyses in individual trials based on baseline 25OHD 
18 RCTs reported the results of a subgroup analysis using various thresholds for baseline 
25OHD (Appendix e12). Three RCTs reported no effects of vitamin D on fracture in 
subgroups, and six reported no effects in subgroups or no interactions with baseline 25OHD, 
and one mixed effects of vitamin D on falls in subgroups. The subgroup results in all RCTs 
were similar to the primary analyses. For BMD, one RCT reported positive effects in 
subgroups, five RCTs mixed effects, and eight RCTs no effects in subgroups or no 
interactions with baseline 25OHD. In 3/14 RCTs, some subgroup results were different to the 
primary analysis, and in the remaining 11 RCTs the subgroups results were similar to the 
primary analysis. 
 
Subgroup analyses in pooled trial datasets 
Appendix e13-14 shows the results of the pre-specified subgroup analyses for the meta-
analyses. For fractures and falls, there was only 1 significant interaction between vitamin D 
supplementation and a factor (trial size for total fracture, effect greater in smaller studies) in 
the 12 subgroup analyses for each of the 3 outcomes (36 total analyses). For BMD, of the 64 
subgroup analyses, there were 8 significant interactions, although in 4 there was only 1 trial 
in one of the subgroups. The remaining 4 significant interactions were for total hip (effect 
greater without co-administered calcium), femoral neck (effect greater in smaller studies or 
without co-administered treatments), and total body (effect greater with higher doses). 
Overall, there were 100 subgroup analyses. If all the results were independent, about 5 
statistically significant interactions would be expected by chance. In post-hoc analyses, we 
compared high daily versus low daily dose RCTs, and intermittent high dose versus 
intermittent low dose RCTs and there were no significant interactions between subgroups for 
any outcome. 
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Discussion 
In meta-analyses of 81 RCTs, vitamin D supplementation did not affect incident fractures or 
falls, and did not have consistent clinically relevant effects on BMD. There were no 
statistically significant differences in results of trials comparing vitamin D with controls and 
trials comparing higher vs lower doses of vitamin D, although there are fewer trials with the 
latter study design. Likewise, there was no consistent evidence of different effects in 
subgroup analyses based upon potentially influential baseline variables including baseline 
25OHD or study design characteristics, nor of different effects in trials of higher dose vitamin 
D or trials with higher achieved 25OHD. Trial sequential analyses showed that there is 
reliable evidence that vitamin D supplementation does not have meaningful clinical benefits: 
it does not reduce the relative risk of total fracture by 5% or falls by 7.5%, it does not 
increase BMD by 0.5-1%, and uncertainty remains as to whether it might increase the risk of 
hip fracture. Further similar trials are unlikely to alter the conclusions of the trial sequential 
analyses. If a large future trial has markedly different results to the current trials, adding its 
results will substantially increase the heterogeneity of the trial results, which in turn will 
reduce the weighting the new large trial receives in the pooled analyses. Thus, adding a 
positive result from a large RCT will have only a small effect on the pooled result, and is 
unlikely to alter the conclusions of the current meta-analyses. 
 
The strengths of the current analyses are that they are comprehensive, include all available 
data from a large number of new trials, and concomitantly assess the major clinical and 
surrogate endpoints for musculoskeletal health. The analyses are based on substantially more 
trials, more participants and more events than previous reviews, which means the analyses 
have greater power, the effect estimates have greater precision, the trial sequential analyses 
are able to examine efficacy at lower risk reduction thresholds, and the subgroup analyses are 
more comprehensive. The trial sequential analyses are important because they provide 
estimates about the reliability of current evidence and the likelihood of future trials changing 
current conclusions. The number of studies included permitted a large number of subgroup 
analyses exploring the effects of potentially relevant trial and participant characteristics, some 
of which have been invoked as explanations for the null findings of individual trials of 
vitamin D. The greater number of trials with BMD as an outcome allowed an examination of 
the effects of vitamin D supplementation in trials of differing durations, which showed no 
evidence that between-group differences in BMD increased as trial duration increased. 
 
The analyses also have limitations. We included studies with methodological limitations, 
although there was no evidence that RCTs at low risk of bias reported substantially different 
effects. Several meta-analyses had moderate heterogeneity in trial results, generally because a 
few small-moderate sized studies reported positive results that were not observed in larger 
RCTs. The subgroup analyses show that for all outcomes smaller studies of shorter duration 
tended to have inflated effect sizes compared with larger and longer studies, such that the 
results of small, short duration studies should be interpreted very cautiously, as they may not 
be replicated in larger, longer studies. Heterogeneity of populations, study designs and results 
is also an issue for trial sequential analyses. While the heterogeneity in the existing RCT 
results is incorporated into the trial sequential analysis calculations, assumptions about the 
results of future large trials are based on the expectation that they will be similar to the 
existing trials. For vitamin D, this seems a reasonable assumption given the consistency 
amongst existing trial results, particularly amongst the existing large RCTs. Data were 
collected differently for falls in different RCTs which may affect trials results, although the 
results were independent of our assessment of the risk of bias.  
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The results from these meta-analyses are consistent with most of the recent systematic 
reviews of vitamin D supplementation on musculoskeletal outcomes,3,6,7,9,10 including those 
from the Cochrane groups,4,5,8 and align with the recent statements from the US Preventative 
Services Taskforce which recommends against vitamin D supplementation to prevent falls108 
or fractures109 in community-dwelling adults. Some previous meta-analyses reached more 
optimistic conclusions, as a result of differences in trial selection and outcome definition, and 
use of per-protocol rather than intention to treat analysis.110,111 This might explain why some 
clinical guidelines continue to recommend vitamin D supplementation for musculoskeletal 
indications112,113 which seems inconsistent with the available evidence.  
 
Previous explanations for the failure of vitamin D to have meaningful effects on 
musculoskeletal outcomes have included that the baseline 25OHD of trial participants have 
been too high, the doses of vitamin D supplements too low, or that trials have been 
inadequately designed, underpowered, or conducted in the wrong populations. None of those 
explanations seems likely to account for the current findings. The trials include a broad range 
of study designs and populations but there are consistently neutral results for all endpoints, 
including the surrogate endpoint of BMD. RCTs of higher doses of vitamin D and RCTs that 
achieved higher 25OHD did not have different results. More than half of trials reported mean 
baseline 25OHD of <50 nmol/L, a cut-off often considered to indicate vitamin D 
insufficiency, and almost all <75 nmol/L. It is possible that trials of populations with much 
lower baseline 25OHD might produce different results because only 4 trials involving 831 
participants reported mean baseline 25OHD <25 nmol/L. 
 
In summary, vitamin D supplementation did not have meaningful effects on fracture, falls, or 
BMD and future trials are unlikely to alter these conclusions. Therefore, there is little 
justification for the use of vitamin D supplements to maintain or improve musculoskeletal 
health, and clinical guidelines should reflect these findings. The clear exception to this is for 
the prevention and/or treatment of the rare conditions of rickets and osteomalacia, which can 
occur after a prolonged lack of sunshine exposure when 25OHD <25 nmol/L. There is also 
no justification for more trials of vitamin D supplements with musculoskeletal outcomes 
because there is no longer equipoise about the effects of vitamin D on these outcomes. Trials 
of vitamin D supplementation in individuals with marked vitamin D deficiency, who are not 
at risk of osteomalacia, might produce different results, but require a strong scientific 
rationale before being undertaken, given the absence of effects of vitamin D seen in the 
existing trials.  
 
 
 
Research in Context: 
 
Evidence before this study 
Early evidence suggested vitamin D supplements might have benefits for musculoskeletal 
health, but more recent systematic reviews have reported no effect of vitamin D 
supplementation on fractures, falls or bone mineral density. Some authors have suggested that 
inadequate vitamin D doses might explain these null results. At least 30 trials of vitamin D 
have been published since the previous systematic reviews, which nearly doubles the 
available trial results for vitamin D for these outcomes. 
 
Added value of this study 
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The meta-analyses and trial sequential analyses show that in a very large body of clinical 
trials vitamin D supplementation does not have clinically relevant effects on fractures, falls, 
and bone mineral density, and this conclusion is unlikely to be altered by future trials with 
similar designs. Effects of higher doses of vitamin D were similar to effects of lower doses, 
and none of the other potential modifiers of vitamin D effects were found to influence 
efficacy for any outcome.  
 
Implications of all the available evidence 
There is little justification for the use of vitamin D supplements to maintain or improve 
musculoskeletal health (except for the prevention or treatment of rickets and osteomalacia in 
high-risk groups), and clinical guidelines should reflect these conclusions.  
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Table 1: Summary of selected characteristics of eligible trials 
 
Characteristics of randomised controlled trials All trials (n=81) 
Population unselected for illness 61 (75%) 
Treatment studied  
 Vitamin D vs controls 39 (48) 
 Vitamin D with agent vs agent 26 (32) 
  Calcium 20 
  Exercise 2 
  Calcium/Exercise 1 
  Other 3 
 High vs low dose vitamin D 16 (20) 
Vitamin D dose >800 IU/d 55 (68) 
Frequency of vitamin D dose  
 Daily  44 (54) 
 Intermittent  36 (44) 
 Mixed 1 (1) 
Duration ≤1 year 55 (68) 
>200 participants 39 (48) 
Community dwelling participants 69 (85) 
Majority of participants female 62 (77) 
Baseline mean age <65 years 33 (41) 
Baseline mean Body Mass Index <30 kg/m2 58 (72) 
Baseline 25-hydroxyvitamin D   
 <25 nmol/L 4 (6) 
 <50 nmol/L 41 (57) 
 <75 nmol/L 71 (99) 
Achieved 25-hydroxyvitamin D  
 50+ nmol/L 69 (91) 
 75+ nmol/L 44 (58) 
Outcome data  
 Fracture 42 (52) 
 Falls 37 (46) 
 Bone mineral density 41 (51) 
 
Data are number of trials (%). 
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Table 2: Results of trial sequential analyses 
 
Outcome  
Incidence/ 
Heterogeneity Effect size Optimum sample size Result 
Total fracture 10%/18% 15% RR 14364 Futile 
36 studies, n=44790  10% RR 33100 Futile 
  7.5% RR 59536 Futile 
  5% RR 135507 Futile 
     
Hip fracture 2.5%/15% 20% RR 32495 Futile 
20 studies, n=36655  15% RR 57722 Uncertaina 
     
Falls 40%/76% 15% RR 8638 Futile 
37 studies, n=34144  10% RR 19643 Futile 
  7.5% RR 35098 Futile 
  5% RR 79344 Uncertainb 
     
Lumbar spine 
BMD -/50% 3% difference 144 Not assessible  
33 studies, n=5198  2% difference 327 Futile 
  1% difference 1304 Futile 
  0.5% difference 5212 Benefit 
     
Total hip BMD  3% difference 46 Not assessible 
28 studies, n=4572 -/64% 2% difference 104 Not assessible 
  1% difference 409 Futile 
  0.5% difference 1627 Futile 
     
Femoral neck BMD  3% difference 128 Not assessible 
26 studies, n=4311 -/73% 2% difference 285 Benefit 
  1% difference 1140 Futile 
  0.5% difference 4561 Benefit 
     
Forearm BMD  3% difference 27 Not assessible 
10 studies, n=1096 -/15% 2% difference 60 Not assessible 
  1% difference 237 Futile 
  0.5% difference 947 Futile 
     
Total Body BMD -/82% 3% difference 59 Not assessible 
15 studies, n=2793  2% difference 135 Not assessible 
  1% difference 535 Futile 
  0.5% difference 2138 Futile 
 
BMD- bone mineral density, RR- risk reduction. Not assessable- analyses were not possible 
because the optimum sample size was smaller than the sample size for the first trial. 
a effect size lay between the futility and inferior boundaries 
b effect size lay between the futility and superior boundaries  
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Figure 1: The top panel shows random effects meta-analyses of vitamin D supplementation 
on total fracture. Vit D vs controls refers to trials of vitamin D with controls in unselected 
populations, High vs Low dose to trials of higher and lower dose vitamin D in unselected 
populations, and Selected Population to trials of vitamin D with controls in populations with 
an underlying illness. The bottom panel shows trial sequential analysis of all trials of vitamin 
D on total fracture for a relative risk (RR) of 7.5%. The z-curve is a measure of treatment 
effect, and the boundaries are thresholds for statistical significance adjusted for heterogeneity 
of trial results and multiple statistical testing. A treatment effect outside the statistical 
significance boundary (dashed line) indicates that there is reliable evidence of a treatment 
effect, and a treatment effect within the futility boundary (dotted line) indicates that there is 
reliable evidence of no treatment effect. Optimal size indicates the calculated optimum 
sample size for statistical inference and N indicates the number of participants in the meta-
analysis. 
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Figure 2: The top panel shows random effects meta-analyses of vitamin D supplementation 
on hip fracture. Vit D vs controls refers to trials of vitamin D with controls in unselected 
populations, High vs Low dose to trials of higher and lower dose vitamin D in unselected 
populations, and Selected Population to trials of vitamin D with controls in populations with 
an underlying illness. The bottom panel shows trial sequential analysis of all trials of vitamin 
D on hip fracture for a relative risk (RR) of 15% (see Figure 1 for detailed description).  
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Figure 3: The top panel shows random effects meta-analyses of vitamin D supplementation 
on falls. Vit D vs controls refers to trials of vitamin D with controls, High vs Low dose to 
trials of higher and lower dose vitamin D, sensitivity analysis to trials where falls data were 
gathered only in a subset of participants or for only part of the trial duration. Trials in all 3 
categories were conducted in unselected populations. Selected Population refers to trials of 
vitamin D with controls in populations with an underlying illness. The bottom panel shows 
trial sequential analysis of all trials of vitamin D on falls for a relative risk (RR) of 7.5% (see 
Figure 1 for detailed description). 
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Figure 4: The top panel shows random effects meta-analyses of vitamin D supplementation 
on lumbar spine bone mineral density (BMD) by trial duration and the pooled analysis of all 
trials using the final time point. The bottom panel shows trial sequential analysis of all trials 
of vitamin D on lumbar spine BMD for a mean difference of 0.5% (see Figure 1 for detailed 
description). 
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Figure 5: The top panel shows random effects meta-analyses of vitamin D supplementation 
on total hip bone mineral density (BMD) by trial duration and the pooled analysis of all trials 
using the final time point. The bottom panel shows trial sequential analysis of all trials of 
vitamin D on total hip BMD for a mean difference of 0.5% (see Figure 1 for detailed 
description). 
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Figure 6: The top panel shows random effects meta-analyses of vitamin D supplementation 
on femoral neck bone mineral density (BMD) by trial duration and the pooled analysis of all 
trials using the final time point. One study (Zheng 2018) has clearly outlying results – 
difference 10.6% (95%CI 9.0-12.3). Excluding this trial, reduces the effect size at 1y to 
0.81% (0.37-1.25). Because of its disproportionate effect, this result was excluded from 
further analyses. The bottom panel shows trial sequential analysis of all trials of vitamin D on 
femoral neck BMD for a mean difference of 0.5% (see Figure 1 for detailed description). 
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Appendix: 
 
e1. Table: Literature Searches 
 
Database  Search Terms Citations 
December 2015   
Pubmed Vitamin D with clinical trials filter 4018 
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Within title: (“Vitamin D” or “cholecalciferol” or “colecalciferol” or “ergocalciferol” or “calciferol”) and 
(random* or “trial”) 631 
Pubmed Vitamin D, publication date after 1/1/2015 634 
Pubmed Systematic reviews or Meta-analyses of randomized controlled trials of vitamin D with clinical endpoints  38 
   
September 2017   
Pubmed vitamin D AND (falls or fracture or ("bone density") or ("bone mineral") or ("bone mass")); June 2015- on 1575 
   
Embase 1. vitamin D/ 64209 
 2. falling/ 33692 
 3. fracture/ 80482 
 4. bone density.mp. or bone density/ 82944 
 5. bone mineral.mp. or bone mineral/ 63614 
 6. bone mass.mp. or bone mass/ 32201 
 7. 4 or 5 or 6 111659 
 8. 2 or 3 or 7 206968 
 9. 1 and 8 14680 
 10. limit 9 to yr="2015 -Current" 2555 
   
Cochrane #1 "vitamin D" Publication Year from 2015 to 2017 (Word variations have been searched) 1776 
 
#2 "falls" or "fracture" or "bone mineral" or "bone density" or "bone mass" Publication Year from 2015 to 
2017 (Word variations have been searched) 5945 
 #3 #1 and #2  420 
   
February 2018   
Pubmed vitamin D AND (falls or fracture or ("bone density") or ("bone mineral") or ("bone mass")) June 2017- on 476 
   
Embase 1. vitamin D/ 65390  
 2. falling/ 34199  
 3. fracture/ 81571  
 4. bone density.mp. or bone density/ 84341  
 5. bone mineral.mp. or bone mineral/ 64576  
 6. bone mass.mp. or bone mass/ 32585  
 7. 4 or 5 or 6 113405  
 8. 2 or 3 or 7 210079  
 9. 1 and 8 14871  
 10. limit 9 to yr="2017 -Current" 853  
   
Cochrane #1 "vitamin D" Publication Year from 2017 to 2018 (Word variations have been searched) 643 
 
#2 "falls" or "fracture" or "bone mineral" or "bone density" or "bone mass" Publication Year from 2017 to 
2018 (Word variations have been searched) 2742 
 #3 #1 and #2  137 
   
Clinical trials. gov 24 new potentially relevant trials- 20 ongoing/recently completed; 4 new citations 4 
   
WHO portal 5 new potentially relevant trials- 2 ongoing/recently completed; 3 new citations 3 
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e2. Table: Ineligible potentially relevant randomised controlled trials  
 
Reference Reason for exclusion Outcome 
RCTs included in previous meta-analyses  
Christiansen 1980114 BMD not measured with DXA BMD 
Mobarhan 1984115 BMD not measured with DXA BMD 
Chapuy 1992116,117 Co-adminstered calcium and vitamin D vs placebo Falls/Fracture/BMD 
Vogelsang 1995118 BMD not measured with DXA BMD 
Dawson-Hughes 1997119 Co-adminstered calcium and vitamin D vs placebo Fracture/BMD 
Baeksgaard 1998120 Co-adminstered calcium and vitamin D vs placebo BMD 
Tuppurainen 1998121 Co-adminstered calcium and vitamin D vs placebo BMD 
Krieg 1999122 Co-adminstered calcium and vitamin D vs placebo Fracture 
Peichl 1999123 Other co-interventions in treatment but not controls Falls 
Harwood 200444 Co-adminstered calcium and vitamin D vs placebo arms excluded Fracture/Falls/BMD 
Larsen 2004124 Co-adminstered calcium and vitamin D vs placebo Fracture 
Meier 2004125 Co-adminstered calcium and vitamin D vs placebo BMD 
Larsen 2005126 Co-adminstered calcium and vitamin D vs placebo Falls 
Porthouse 2005127  Co-adminstered calcium and vitamin D vs placebo Falls/Fracture 
Sato 2005128 Retracted Falls/Fracture 
Arden 2006129 Duplicate data Falls 
Bischoff-Ferrari 2006130 Co-adminstered calcium and vitamin D vs placebo Falls 
Jackson 200620 Co-adminstered calcium and vitamin D vs placebo Fracture/BMD 
Bolton-Smith 2007131 Co-adminstered calcium and vitamin D vs placebo Fracture 
Berggren 2008132 Other co-interventions in treatment but not controls Falls 
Grieger 2009133 Other co-interventions in treatment but not controls Falls 
Pfeifer 2009134 Data inaccuracy Falls/Fracture 
Viljakainen 2009135  BMD not measured with DXA  
Salovaara 2010136 Co-adminstered calcium and vitamin D vs placebo BMD/Fracture/Falls 
Karkkainen 2010137 Co-adminstered calcium and vitamin D vs placebo BMD/Fracture/Falls 
   
Other RCTs excluded on full text review  
Takizawa 1980138 BMD not measured with DXA BMD 
Tjellesen 1983139 BMD not measured with DXA BMD 
Imaoka 2016140 Other co-interventions in treatment but not controls Falls 
Hin 201797 BMD not measured with DXA BMD 
Mager 2017141 No post-baseline BMD measurement BMD 
Kruger 2017142 Other co-interventions in treatment but not controls BMD 
Wei 2017143 Pregnancy BMD 
   
Potential relevant RCTs but unable to obtain sufficient data  
Venkatachalam 2003144  Author unable to provide further data BMD 
Lappe 2007145 Author and co-authors didn't respond to emails  BMD/Fractures 
Mieczkowski 2014146 Author didn't respond to emails  BMD 
Maity 2015147 Author didn't respond to emails  BMD 
Peppone 2017148 Author unable to provide further data BMD 
Tan 2017149 Author didn't respond to emails BMD 
Vos 2017150 Author unable to provide further data BMD 
   
Trials reporting falls data without complete fracture data  
Bischoff 200338 Author didn't respond to emails  Falls 
Latham 200340 Author didn't respond to emails  Falls 
Dhesi 200443 Fracture data not gathered Falls 
Broe 200752 Fracture data not gathered Falls 
Rizzoli 201482 Fracture data not gathered Falls 
Houston 201587 Fracture data not gathered Falls 
Bischoff-Ferrari 201615 Author didn't respond to emails  Falls 
Jin 201691 Fracture data not gathered Falls 
  
 
Trials identified from registries  
Enishi Authors replied, final data not available yet JPRN-UMIN000008361 
Wang Authors replied, final data not available yet ChiCTR-PRC-09000518 
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Hillier  Author didn't respond to emails NCT01119131 
Elliot Author didn't respond to emails NCT00204919 
Vestergaard Authors replied, final data not available yet NCT01932931 
 
Abbreviations: RCT- randomised controlled trial, BMD- bone mineral density, DXA- dual energy x-ray 
absorptiometry,   
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e3. Figure: study flow 
 
 
 
a Previous systematic reviews3,6,8,9,16,17 
Abbreviations: RCT- randomised controlled trial, CaD- co-administered calcium and vitamin D 
 
 
 
 
 
23 
articles
Database search: 
4276 citations
Potentially relevant articles from
our previous systematic reviewsa
(n=120)
81 RCTs eligible for inclusion
42 Fracture outcome data
37 Falls outcome data
41 Bone density outcome data
3 articles report separate outcomes 
from same RCT 
Articles excluded (n=61)
40 CaD
11 Duplicate
8 No eligible outcome
1 Data unreliable
Articles identified from 
other systematic reviews
(n=7)
4253 excluded
4035 Not RCT
25 CaD
128 Duplicate
15 Ineligible agent
22 No eligible outcome
28 Not adults
67
articles
7 
trials
Registry search: 
30 potentially 
relevant trials
23 excluded
22 Likely ongoing
1 Not adults
13 excluded
12 insufficient data  available
1 trial in pregnant women
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e4. Table: Study design and selected baseline characteristics of included trials. 
 
Participants 
( Vit D/ 
Control)a 
Age 
(y) 
Gender 
(% F) Duration Treatment groups Vit D Dose 
Primary 
Endpoint 
Secondary 
Endpoint 
Dawson-Hughes 199127 139/137 62 100 12m CaD, Ca+Placebo 400IU/d Bone density 
 Dawson-Hughes 199528 131/130 64 100 2y CaD 100 or 700IU/d Bone density 
 Ooms 199529 177/171 80 100 2y Vit D, Placebo 400IU/d Fracture Bone density 
Graafmans 199630 177/177 83 85 28w Vit D, Placebo 400IU/d Fracture Falls 
Lips 199631 1291/1287 80 74 4y Vit D, Placebo 400IU/d Fracture Falls 
Komulainen 1998/199932,33 232/232 53 100 5y 2*2 factorial: Vit D, HRT, Placebo 300IU/d for 4y then 100IU/d  Bone density Fracture  
Hunter 200034  79/79 59 100 2y Vit D, Placebo 800IU/d Bone density 
 Pfeifer 200035 74/74 74 100 1y CaD, Ca 800IU/d Body sway Falls/Fracture 
Patel 200136  35/35 47 100 2y Vit D, Placebo 800IU/d Biochemistry Bone density 
Meyer 200237 569/575 85 76 2y Vit D, Placebo 400IU/d Fracture 
 Bischoff 200338 62/60 85 100 12w CaD, Ca 800IU/d Falls Fracture 
Cooper 200339  93/94 56 100 2y CaD, Ca+Placebo 10,000IU/w Bone density 
 Latham 200340 121/122 79 65 6m Vit D, Placebo 300,000IU stat Health Falls  
Trivedi 200341 1345/1341 75 24 5y Vit D, Placebo 100,000IU/3m Fracture Falls 
Avenell 200442  70/64 77 83 46m 2*2 factorial: Vit D, Ca, Control 800IU/d Compliance Fracture 
Dhesi 200443 70/69 77 78 6m IM Vit D, Placebo 600,000IU stat Reaction Time Falls 
Harwood 200444 38/37 81 100 12m IM Vit D, Control 300,000IU stat Bone density Falls/Fracture 
Aloia 200545  104/104 61 100 3y CaD, Ca+Placebo 800IU/d for 24m then 2000IU/d Bone density 
 Flicker 200546 313/312 83 95 2y CaD, Ca+Placebo 10,000IU/w then 1000IU/d Falls  Fracture 
Grant 200547 2649/2643 77 85 45m 2*2 factorial: Vit D, Ca, Placebo 800IU/d Fracture Falls 
Wissing 200548a 46/44 43 43 1y CaD, Ca 25,000 IU/m Bone density 
 Bunout 200649a 48/48 77 90 9m 2*2 factorial: CaD, Exercise 400IU/d Muscle strength Bone density/falls 
Law 200650a 1762/1955 85 76 10m Vit D, Control (cluster) 100,000IU/3m Fracture Falls 
Mikati 200651a 57/49 29 54 1y Vit D 400 or 4000IU/d Bone density 
 Broe 200752 99/25 89 73 5m Vit D, Placebo 200, 400, 600 or 800IU/d Biochemistry Falls 
Burleigh 200753 101/104 83 59 1m CaD, Ca 800IU/d Falls Fracture 
Lyons 200754 1725/1715 84 76 3y Vit D, Placebo 100,000IU/4m Fracture 
 Smith 200755 4727/4713 79 54 3y IM Vit D, Placebo 300,000IU/y Fracture Falls 
Andersen 200856  117/56 37 51 1y Vit D, Placebo 400 or 800IU/d Bone density 
 Prince/Zhu 2008a57,58 151/151 77 100 1y CaD, Ca+Placebo 1000IU/d Falls Fracture/Bone density 
Zhu 2008b59 39/40 75 100 5y CaD, Ca 1000IU/d Bone density 
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Bischoff-Ferrari 201014a 86/87 84 79 12m 2*2 factorial: Vit D, Physiotherapy 800, or 2000IU/d Falls Fracture 
Islam 201060  50/50 23 100 12m Vit D, Placebo 400IU/d Bone density 
 Jorde 201061  279/142 47 63 1y CaD, Ca+Placebo 20,000 or 40,000IU/w Biochemistry Bone density 
Janssen 201062a 36/34 81 100 6m CaD, Ca+Placebo 400IU/d Muscle strength Fracture 
Sanders 201013 1131/1125 76 100 3-5y Vit D, Placebo 500,000IU/y Fracture Falls 
Witham 201063a 53/52 80 34 20w Vit D, Placebo 100,000IU/10w 6 min walk Falls/Fracture 
Mitri 201164a 46/46 57 51 16w 2*2 factorial: Vit D, Ca, Placebo 2000IU/d Biochemistry Fracture 
Papaioannou 201165a 44/21 78 55 3m Vit D, Placebo 50,000 or 100,000IU stat Biochemistry Fracture 
Rastelli 201166  30/30 62 100 6m CaD, CaD+Placebo 
50,000IU/w for 8-16wk then 
50,000IU/m Pain Bone density 
Steffensen 201167  35/36 40 71 96w CaD, Ca+Placebo 20,000IU/w Bone density Fractures 
Verschueren 201168 56/57 80 100 6m 2*2 factorial: Vit D, Exercise 880 or 1600IU/d Muscle strength Bone density 
Glendenning 201269 353/333 77 100 9m Vit D, Placebo 150,000IU/3m Falls Fracture 
Grimnes 201270  149/148 63 100 1y CaD, CaD+Placebo 20,000IU twice/w Bone density 
 Nieves 201271  64/63 62 100 2y CaD, Ca+Placebo 1000IU/d Bone density 
 Iuliano-Burns 201272a 75/35 41 17 12m Vit D 50,000IU /m or /2m Biochemistry Bone density 
Bolland 201373a 13/14 57 70 1y Vit D, Placebo 50,000IU/m Biochemistry Bone density 
MacDonald 2013/Wood 
201474,75a 203/102 65 100 12m Vit D, Placebo 400 or 1000 IU/d Bone density Falls/Fractures 
Punthakee 201376a 607/614 67 41 6m 
3*2 factorial: Vit D, Pioglitazone, 
Rosiglitazone, Placebo 1000IU/d Death or cancer Fracture 
Wamberg 201377a 26/26 40 71 6m Vit D, Placebo 7000IU/d Biochemistry Bone density 
Witham 201378a 80/79 77 48 12m Vit D, Placebo 100,000IU/3m Blood pressure Falls 
Breslavsky 201479a 24/23 66 53 12m Vit D, Placebo 1000 IU/d Biochemistry Fractures 
Massart 201480a 26/29 64 38 13w Vit D, Placebo 25,000IU/w Biochemistry Fracture 
Norenstedt 201481a 75/75 60 79 1y CaD, Ca 1600IU/d Biochemistry Bone density 
Rizzoli 201482a 413/105 67 91 6m Vit D, control 1000IU/d 25OHD Falls 
Rolighed 201483a 23/23 59 76 1y Vit D, Placebo 2800IU/d Biochemistry Bone density 
Baron 201584a 1130/1129 58 37 3-5y 2*2 factorial: Vit D, Ca, Placebo 1000IU/d Colorectal adenoma Fracture 
Cangussu 201585a 80/80 59 100 9m Vit D, Placebo 1000IU/d Falls 
 
Hansen 201586a 154/76 61 100 12m Vit D, Placebo 
800 IU/d or 50,000 IU/d for 15d 
then 50,000 IU/2w Calcium absorption Bone density/Falls/Fracture 
Houston 201587a 38/30 78 72 5m Vit D, Placebo (cluster) 100,000IU/ m Adherence Falls 
Liyanage 201588a 42/43 58 55 6m IM Vit D, Placebo 50,000IU/m Biochemistry Bone density 
Uusi-Rasi 201589a 204/205 74 100 2y 2*2 factorial: Vit D, Exercise 800 IU/d Falls Bone density 
Aspray 201690a 253/126 75 48 12m Vit D 12,000, 24,000 or 48,000IU/m  Bone density Falls 
Bischoff-Ferrari 201615a 67/67 78 67 12m Vit D 24,000 or 60,000IU/m Physical performance Falls 
Page 41 of 65 
 
Jin 201691a 209/204 63 50 24m Vit D, Placebo 50,000 IU/m Cartilage volume Falls 
Mak 201692a 111/107 84 77 4w Vit D, Placebo 250,000IU stat Gait velocity Falls/Fractures 
Mason 201693a 109/109 60 100 12m Vit D, Placebo 2000IU/d Weight loss Bone density 
Aloia 201794a 130/130 68 100 3y CaD, Ca+Placebo 
Vit D to keep 25OHD > 
75nmol/L Bone density Falls 
Eckard 201795a 66/36 20 36 12m Vit D 18,000, 60,000 or 120,000IU/m  Bone density 
 
Ginde 201796a 55/52 81 58 12m Vit D 12,000 or 100,000IU/m 
Acute respiratory 
infection Falls/Fractures 
Hin 201797a 204/101 72 49 12m Vit D, Placebo 2000 or 4000IU 25OHD Falls/Fracture 
Khaw 201798,103a 2558/2552 65.9 42 3.4y Vit D, Placebo 
200,000IU stat then 
100,000IU/m Cardiovascular disease Falls/Fractures 
Larsen 201799a 256/255 62 39 5y Vit D, Placebo 20,000IU/w Incidence of diabetes Bone density/Fractures 
Levis 2017100a 66/64 72 0 9m Vit D, Placebo 4000IU/d Physical performance Falls 
Pop 2017101a 57/24 58 100 1y CaD, CaD+placebo, CaD+placebo 10,000 or 25,000IU/w Bone density 
 Rahme 2017102a 129/128 71 55 1y CaD, CaD+Placebo 10,000IU/w Bone density 
 Reid 201798,103a 228/224 69 37 2y Vit D, Placebo 200,000IU then 100,000IU/m Cardiovascular disease Bone density 
Schwetz 2017104a 249/243 65 35 6m Vit D, Placebo 540,000IU stat then 90,000IU/m Hospital stay Falls/Fractures/Bone density 
Smith 2017105a 235/38 66 100 12m Vit D, Placebo 
400, 800, 1600, 2400, 3200, 
4000, or 4800IU/d 25OHD Falls/Fractures 
Havens 2018106a 109/105 22 16 48w CaD, CaD+placebo 50,000IU/q4w Bone density 
 Zheng 2018107a 30/30 66 45 24w Vit D, Placebo 5000IU/d Biochemistry Bone density 
 
a Trial not included in our previous systematic reviews
3,6,9 
Abbreviations: Vit D- vitamin D; CaD- co-administered calcium and vitamin D; Ca- calcium; HRT- hormone replacement therapy; IM-intramuscular; 25OHD- 25 
hydroxyvitamin D  
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e5. Table: Further selected baseline characteristics of included trials. 
 
Country Population 
Residental 
status 
BMI (or 
Weight) 
(kg/m2) 
Additional agent 
in both groups 
Baseline 
25OHD 
(nmol/L)  
Achieved 
25OHD 
(nmol/L) Assay 
Dawson-Hughes 1991 USA White, postmenopausal Community 68kg Ca 380 mg/d NS 95/71 (All) CBP 
Dawson-Hughes 1995 USA White, postmenopausal Community 26 Ca 500 mg/d  NS 100/66 (All) CBP 
Ooms 1995 Netherlands Residential care , > 70y Institution 28  26/27 (All) 62/23 (All) HPLC 
Graafmans 1996 Netherlands Residential care, substudy of Lips Institution NS  NS NS  
Lips 1996 Netherlands >70y Institution NS  26/27 (270) 54/23 (96) HPLC 
Komulainen 1998/1999 Finland Postmenopausal Community 26 
Ca 93 mg/d in Vit 
D/Placebo groups 26/29 (35/34) 35/26 (35/34) HPLC 
Hunter 2000  UK Twins Community 24  71/70 (All) 105/80 (All) Incstar 
Pfeifer 2000 Germany >70y Community 25 Ca 1.2 g/d 26/25 (All) 66/43 (All) Nichols RIA 
Patel 2001  UK Healthy Females Community 25  68/76 (All) +25 (All) Incstar 
Meyer 2002 Norway Residential care Institution 22  47/51 (31/34) 64/46 (31/34) HPLC 
Bischoff 2003 Switzerland Residential care Institution 25 Ca 1.2 g/d 31/29 (All) 66/29 (All) Nichols RIA 
Cooper 2003  Australia Postmenopausal Community 67kg Ca 1g/d 82/83 (All) 81/70 (All) Incstar 
Latham 2003 NZ Frail and in hospital Community 25 Exercise 38/48 (All) 60/48 (All) Diasorin RIA 
Trivedi 2003 UK Mainly UK doctors Community 24  NS 
74/53 
(124/114) NS 
Avenell 2004  UK Previous fracture Community NS Ca 1g/d in 2 groups NS NS  
Dhesi 2004 UK Falls clinic Community 27  27/25 (All) 44/32 IDS 
Harwood 2004 UK Recent hip fracture Community 24  28/30 (All) 40/27 (25/32) Incstar RIA 
Aloia 2005  USA African American, postmenopausal Community 30 Ca up to 1.2-1.5 g/d 48/43 (All) 71/NS (All) Diasorin RIA 
Flicker 2005 Australia Residential care Institution 60kg Ca 600 mg/d NS NS  
Grant 2005 UK Previous fracture Community 65kg Placebo or Ca 1g/d 38 (60) 62/44 (60) HPLC 
Wissing 2005 Belgium Renal transplant receiving steroids Community 24 Ca up to 2g/d 61/49 (All) 67/41 (All) Diasorin RIA 
Bunout 2006 Chile 25OHD < 40 Community 29 
Exercise or nil, Ca 800 
mg/d 31/33 (All) 65/36 (All) Not stated 
Law 2006 UK Residential Care Institution NS  59/NS (18) 99/NS (18) IDS 
Mikati 2006 Lebanon Anticonvulsants Community 26  34/33 (All) 66/44 (All) Incstar 
Broe 2007 US Residential care Institution  25  48/53 (All) 63/60 (All) NS 
Burleigh 2007 UK Hospital ATR ward Institution  NS Ca 1.2 g/d 25/22 (54) 27/22 (NS) Nichols RIA 
Lyons 2007 UK Residential care Institution NS  NS 80/54 (102) Diasorin RIA 
Smith 2007 UK GP register Community NS  56.5 (43) +21%/NS (NS) Nichols RIA 
Andersen 2008  Denmark Pakistanis in Denmark Community 27  16/16 (All) 46/15 (All) HPLC 
Prince/Zhu 2008a Australia Recent fall Community 29 Ca 1 g/d 45/44 (All) 60/44 (All) Diasorin RIA 
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Zhu 2008b Australia Postmenopausal Community 70kg Ca 1.2 g/d 70/67 (All) 106/64 (All) CBP 
Bischoff-Ferrari 2010 Switzerland Post hip fracture Community 24 
Ca 1g/d, 
Standard/extended 
physiotherapy 33/31 (All) 89/112 (All) Diasorin RIA 
Islam 2010  Bangladesh Factory workers Community 22  37/35 (All) 69/36 (All) IDS 
Jorde 2010  Norway Overweight Community 35 Ca 500 mg/d 59/60 (All) 122/56 (All) Diasorin RIA 
Janssen 2010 Netherlands >65y Institution 26 Ca 500 mg/d 33/34 (All) 77/42 (All) NS 
Sanders 2010 Australia >70y Community NS  53/45 (74/57) 
55-74/~40-50 
(16-57/20-49) Diasorin RIA 
Witham 2010 UK CHF, >70y, 25OHD <50 nmol/L Community 27  21/24 (All) 41/25 (All) RIA 
Mitri 2011 USA Glucose intolerance/diabetes Community 32 Placebo or 800 mg/d 61/62 (All) 77/46 (All) HPLC 
Papaioannou 2011 Canada Post hip fracture Community 69kg Vit D 1000IU/d 48/47 (27/18) 79/87 (All) Diasorin 
Rastelli 2011  USA Past breast cancer using anastrozole Community 32 Ca 1g/d, vit D 400IU/d  58/55 (All) 74/64 (All) Diasorin Liaison 
Steffensen 2011  Norway Multiple sclerosis Community 26 Ca 500 mg/d 56/57 (All) 123/62 (All) LCMS/MS 
Verschueren 2011  Belgium Residential care , > 70y Institution 27 
Vibration or nil, 
Calcium 1 g/d 55/52 (All) 157/138 (All) Diasorin RIA 
Glendenning 2012 Australia >70y Community 27  65/67 (20/20) 75/60 (20/20) Liaison 
Grimnes 2012  Norway Low BMD Community 25 Ca 1g/d, vit D 800IU/d 71/71 (All) 186/90 (All) LCMS/MS 
Nieves 2012  USA African American, Postmenopausal Community 31 Ca to 1 g/d total intake 29/29 (All) 55/32 (All) Diasorin RIA 
Iuliano-Burns 2012 Australia Antarctic explorers Community 85kg  58/63 (All) 66/54 (All) Roche 
Bolland 2013 New Zealand Sarcoidosis Community 27  40/45 (All) 79/47 (All) LCMS/MS 
MacDonald 2013/Wood 2014 UK Postmenopausal, white Community 25  33/36 (All) 70/32 (All) LCMS/MS 
Punthakee 2013 Multinational Diabetes Mellitus Community 31 
Pioglitazone, 
rosiglitazone, or 
placebo NS NS  
Wamberg 2013 Denmark Obese Community 36  35/35 (All) 110/47 (All) LCMS/MS 
Witham 2013 UK Systolic hypertension Community 28  45/45 (All) 67/48 (All) IDS 
Breslavsky 2014 Israel Diabetes Mellitus Community 29  27/34 (All) 42/35 (All) NS 
Massart 2014 Belgium Haemodialysis Community 27  46/43 (All) 88/41 (All) Liaison 
Norenstedt 2014 Sweden Post parathyroidectomy Community 26 Ca 1 g/d 40/45 (All) 73/51 (All) Diasorin Liaison 
Rizzoli 2014 13 countries Osteoporosis Community 25 
Strontium 2 g/d, 
Calcium 1 g/d 44/44 (All) 67/45 (All) Diasorin RIA 
Rolighed 2014 Denmark Pre/Post parathyroidectomy Community 81kg  50/57 (All) 105/63 (All) LCMS/MS 
Baron 2015 USA Recent colorectal adenoma removed Community 29 Placebo or Ca 1.2 g/d 61/61 (All) 81/NS (All) IDS 
Cangussu 2015 Brazil Recent fall Community 30  38/42 (All) 69/35 (All) HPLC 
Hansen 2015 USA 25OHD 35-68 nmol/L, no osteoporosis Community 31  53/53 (All) 86/45 (All) HPLC 
Houston 2015 USA Meals on Wheels programme Community NS  56/47 (All) 106/56 (All) Liaison 
Liyanage 2015 Sri Lanka Diabetic nephropathy Community 24  56/50 (All) 82/46 (All) Vitros 
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Uusi-Rasi 2015 Finland Recent fall Community 28  63/69 (All) 93/69 (All) IDS 
Aspray 2016 UK Older men and women Community 27  41/43 (All) 80/61 (All) LCMS/MS 
Bischoff-Ferrari 2016 Switzerland Recent fall Community 26  47/52 (All) 100/76 (All) LCMS/MS 
Jin 2016 Australia Osteoarthritis Community 30  44/44 (All) 84/51 (All) Liaison 
Mak 2016 Australia Hip fracture surgery 
83% 
Community 25 
Ca 500 mg/d, Vit D 
800IU/d 56/50 (All) 80/72 (All) Diasorin 
Mason 2016 US Overweight undertaking weight loss Community 32 
Weight loss 
programme 54/54 (All) 88/50 (All) Diasorin Liaison 
Aloia 2017 US African American Community NS Ca to 1 g/d total intake NS/NS 94/52 (All) NS 
Eckard 2017 US HIV Community 23  45/43 (All) 87/74 (All) IDS or ADVIA 
Ginde 2017 USA Residential Care Institution 27  58/58 (All) 77/65 (All) LCMS/MS 
Hin 2017 UK >65y Community 27  52/47 (All) 120/53 (All) Access 2 
Khaw 2017 New Zealand 50-84y Community 28  64/63 (All) 
135/66 
(171/163) LCMS/MS 
Larsen 2017 Norway Prediabetes Community 30  60/62 (All) 122/67 (All) LCMS/MS 
Levis 2017 USA 65-90y Community 31  58/57 (All) 115/60 (All) LCMS/MS 
Pop 2017 US BMI>25 Community 30 
Vit D to 600IU/d, Ca 
to 1.2 g/d total intake, 
Weight loss 
programme 69/67 (39/19) 96/76 (39/19) Diasorin RIA 
Rahme 2017 Lebanon BMI>25 Community 30 
Ca 1 g/d, Vit D 
500IU/d 52/50 (All) 90/65 (All) LCMS/MS 
Reid 2017 New Zealand Substudy of Khaw Community 82kg  55/56 (All) 129/60 (All) LCMS/MS 
Schwetz 2017 Austria ICU Community 28  33/33 (All) 115/66 (37/43) IDS 
Smith 2017 USA 25OHD 13-50 nmol/L Community 31  36/36 (All) NS Diasorin 
Havens 2018 US HIV taking tenofovir Community 24 
Multivit (400IU/d vit 
D, Ca 162 mg/d) 39/42 (All) 92/52 (All) IDS 
Zheng 2018 Taiwan Secondary HPT on Haemodialysis Community 22 Cinacalcet, Calcitriol 46/48 (All) 94/59 (All) Immundiagnostik 
 
BMI- body mass index; 25OHD- 25 hydroxyvitamin D; CHF- congestive heart failure; ICU- intensive care unit; HPT- hyperparathyroidism; NS- not stated; Ca- calcium; Vit 
D- vitamin D; CBP- competitive binding protein; HPLC- high performance liquid chromatography; RIA- radioimmunoassay; LSMS/MS- liquid chromatography tandem 
mass spectometry  
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e6. Table: Assessment of risk of bias in included trials 
 
Random 
sequence 
generation 
described 
Allocation 
concealment 
Blinding of  
participants/ 
personnel 
Blinding 
of 
outcome 
assessment 
Incomplete 
outcome 
data 
Differential 
loss to 
follow-up 
Selective 
reporting 
Definition  
of falls 
Duration of  
recall of falls 
(risk of bias) 
Overall 
assessment 
of risk of 
bias falls 
Overall 
assessment 
of risk of 
bias 
fracture 
Overall 
assessment 
of risk of 
bias bone 
density 
Dawson-Hughes 1991 Not stated Not stated Double-blind Yes Yes No No 
    
Moderate 
Dawson-Hughes 1995 Not stated Not stated Double-blind Yes Yes No No 
    
Moderate 
Ooms 1995 Yes Yes Double-blind Yes Yes No No 
    
Low 
Graafmans 1996 Yes Yes Double-blind Yes Yes Not stated No Yes 1w (Low) Moderate 
  Lips 1996 Yes Yes Double-blind Yes No No No 
   
Low 
 Komulainen 1998/1999 Yes Yes No No No No No 
   
Moderate Moderate 
Hunter 2000  Yes Yes Double-blind Yes Yes No No 
    
Moderate 
Pfeifer 2000 Not stated Not stated Double-blind Yes No No No Yes Not stated Moderate Moderate 
 Patel 2001  Not stated Not stated Double-blind Yes No No No 
    
Moderate 
Meyer 2002 Pseudo (DOB) Yes Double-blind Yes No No No 
   
Low 
 Bischoff 2003 Not stated Yes Double-blind Yes Yes No No Yes Daily (Low) Moderate Moderate 
 Cooper 2003  Not stated Not stated Double-blind Yes No No No 
    
Low 
Latham 2003 Yes Yes Double-blind Yes No No No No Daily (Low) Low 
  Trivedi 2003 Yes Yes Double-blind Yes No No No No 12m (High) Moderate Low 
 Avenell 2004  Yes Not stated No Yes No Yes No 
   
High 
 Dhesi 2004 Yes Not stated Double-blind Yes No No No Yes Daily (Low) Moderate 
  Harwood 2004 Yes Yes No No No Yes No No 3-6m (High) High High High 
Aloia 2005  Yes Not stated Double-blind Yes No No No 
    
Low 
Flicker 2005 Yes Yes Double-blind Yes No No No Yes Daily (Low) Low Low 
 Grant 2005 Yes Yes Double-blind Yes No No No No 1w (Low) Moderate Low 
 Wissing 2005 Pseudo No Not stated Not stated Yes Yes No 
    
High 
Bunout 2006 Yes Yes Double-blind Yes No No No No 1m (Low) Low 
 
Low 
Law 2006 Yes Not stated No Yes No No No No NS Moderate Moderate 
 Mikati 2006 Pseudo No Open-label Yes Yes Yes No 
    
High 
Broe 2007 Yes Yes Double-blind Yes No No No Yes Daily (Low) Low 
  Burleigh 2007 Yes Yes Double-blind Yes No No No Yes Daily (Low) Low Moderate 
 Lyons 2007 Yes Yes Double-blind Yes No No No 
   
Low 
 Smith 2007 Not stated Yes Double-blind Yes No No No No 6m (High) Moderate Low 
 Andersen 2008  Yes Yes Double-blind Yes No No No 
    
Low 
Prince/Zhu 2008a Yes Yes Double-blind Yes No No No Yes 6w (Mod) Low Moderate Low 
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Zhu 2008b Yes Yes Double-blind Yes No No No 
    
Low 
Bischoff-Ferrari 2010 Yes Not stated Double-blind Yes No No No Yes Daily (Low) Low Moderate 
 Islam 2010  Not stated Yes Double-blind Yes No Yes No 
    
Low 
Jorde 2010  Not stated Not stated Double-blind Yes No No No 
    
Low 
Janssen 2010 Not stated Yes Double-blind Yes No No No 
   
High 
 Sanders 2010 Yes Yes Double-blind Yes No No No Yes Daily (Low) Low Low 
 Witham 2010 Yes Yes Double-blind Yes No No No No 10w (Mod) Moderate Moderate 
 Mitri 2011 Yes Yes Double-blind Yes No No No 
   
Moderate 
 Papaioannou 2011 Yes Yes Double-blind Yes No No No 
   
High 
 Rastelli 2011  Yes Yes Double-blind Yes No No No 
    
Low 
Steffensen 2011  Yes Yes Double-blind Yes No No No 
   
High Low 
Verschueren 2011  Yes Yes Not stated Yes No No No 
    
Low 
Glendenning 2012 Yes Yes Double-blind Yes No No No Yes Daily (Low) Low Moderate 
 Grimnes 2012  Yes Yes Double-blind Yes No No No 
    
Low 
Nieves 2012  Not stated Not stated Double-blind Yes No Yes No 
    
Low 
Iuliano-Burns 2012 Not stated Not stated Double-blind Yes No No No 
    
Low 
Bolland 2013 Yes Yes Double-blind Yes No No No 
    
Moderate 
MacDonald 2013/Wood 
2014 Yes Yes Double-blind Yes No No No No 2m (Mod) Low Moderate Low 
Punthakee 2013 Yes Yes Double-blind Yes No No No 
   
High 
 Wamberg 2013 Yes Yes Double-blind Yes No No No 
    
Low 
Witham 2013 Yes Yes Double-blind Yes No No No No Daily (Low) Low Moderate 
 Breslavsky 2014 Not stated Not stated Not stated Not stated No No No 
   
High 
 Massart 2014 Yes Not stated Yes Yes No No Yes No Not stated High Moderate 
 Norenstedt 2014 Not stated Not stated Double-blind Yes No No No 
    
Low 
Rizzoli 2014 Not stated Yes Double-blind Yes Yes Yes No Yes Daily (Low) Moderate 
  Rolighed 2014 Yes Yes Double-blind Yes No No No 
    
Moderate 
Baron 2015 Yes Yes Double-blind Yes No No No 
   
Low 
 Cangussu 2015 Yes Yes Double-blind Yes No No No Yes 9m (High) Moderate Moderate 
 Hansen 2015 Not stated Yes Yes Yes No No No No 1-4m (Mod) Low Moderate Low 
Houston 2015 Yes Not stated Single Uncertain No No No No 1m (Low) High 
  Liyanage 2015 Yes Yes Double-blind Yes No No No 
    
Low 
Uusi-Rasi 2015 Yes Yes Double-blind Yes No No No Yes Daily (Low) Low Moderate Low 
Aspray 2016 Not stated Not stated Double-blind Yes No No Yes 
    
Low 
Bischoff-Ferrari 2016 Yes Yes Double-blind Yes No No No Yes Daily (Low) Low 
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Jin 2016 Yes Yes Yes Yes No Yes No No NS High 
  Mak 2016 Yes Yes Double-blind Yes No No No Yes Daily (Low) Low Moderate 
 Mason 2016 Yes Yes Double-blind Yes No No No 
    
Low 
Aloia 2017 Not stated Not stated Double-blind Yes No No No 
 
3m (Mod) Low 
 
Low 
Eckard 2017 Yes Yes Double-blind Yes No No No 
    
Low 
Ginde 2017 Yes Yes Double-blind Yes No No No No Daily (Low) Low Moderate 
 Hin 2017 Yes Yes Double-blind Yes No No No No 6m (High) Moderate Moderate 
 Khaw 2017 Yes Yes Double-blind Yes No No No Yes 1-4m (Mod) Low Low 
 Larsen 2017 Yes Yes Double-blind Yes No No No 
   
Moderate Low 
Levis 2017 Not stated Yes Double-blind Yes No No No No 3m (Mod) Moderate Moderate 
 Pop 2017 Not stated Not stated Double-blind Yes Yes No No 
    
Moderate 
Rahme 2017 Not stated Yes Double-blind Yes No No No 
    
Low 
Reid 2017 Yes Yes Double-blind Yes No No No 
    
Low 
Schwetz 2017 Yes Yes Double-blind Yes Yes Yes No No 6m (High) High High 
 Smith 2017 Yes Yes Double-blind Yes Yes No Yes Yes 3m (Mod) Low Moderate 
 Havens 2018 Not stated Not stated Double-blind Yes No No No 
    
Low 
Zheng 2018 Not stated Not stated Open-label Not stated No No No 
    
Moderate 
 
 
Pseudo- pseudorandomised; DOB- date of birth; Mod- moderate;
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e7. Table: Reported conflicts of interest and funding sources from included trials 
 
 
Conflict of 
Interest 
statement 
Conflict of 
Interest 
exists Funding 
Dawson-Hughes 1991 No Yes Mixed industry/ non-industry 
Dawson-Hughes 1995 No Yes Mixed industry/ non-industry 
Ooms 1995 No Unknown Non-industry, drugs from industry 
Graafmans 1996 No Unknown Non industry, drugs from industry 
Lips 1996 No Unknown Non-industry, drugs from industry 
Komulainen 1998/1999 No Yes Mixed industry/ non-industry 
Hunter 2000  No Unknown Non-industry 
Pfeifer 2000 No Yes Industry funded, run, and co-authored.  
Patel 2001  No Unknown Not stated, drugs from industry 
Meyer 2002 No Yes Industry funded, drugs from industry 
Bischoff 2003 No Yes Mixed industry/non-industry 
Cooper 2003  Yes No Non-industry, drugs from industry 
Latham 2003 No Unknown Non-industry 
Trivedi 2003 Yes No Non-industry 
Avenell 2004  No No Non-industry, drugs from industry 
Dhesi 2004 Yes No Non-industry 
Harwood 2004 No Unknown Industry 
Aloia 2005  Yes No Non-industry 
Flicker 2005 Yes No Non-industry 
Grant 2005 Yes No Non-industry, drugs from industry 
Wissing 2005 No Unknown Not stated 
Bunout 2006 No Unknown Non-industry, drugs and equipment from industry 
Law 2006 No Unknown Non-industry 
Mikati 2006 Yes No Non-industry 
Broe 2007 No Unknown Non-industry 
Burleigh 2007 No Unknown Not stated, drugs from industry 
Lyons 2007 No Unknown Non-industry 
Smith 2007 Yes No Non-industry 
Andersen 2008  Yes No Non-industry 
Prince/Zhu 2008a Yes No Non-industry, drugs from industry 
Zhu 2008b Yes No Non-industry 
Bischoff-Ferrari 2010 Yes No Non-industry 
Islam 2010  Yes No Non-industry, drugs from industry 
Jorde 2010  Yes No Non-industry, drugs from industry 
Janssen 2010 No Unknown Non-industry 
Sanders 2010 Yes No Non-industry 
Witham 2010 Yes No Non-industry 
Mitri 2011 Yes No Non-industry, drugs from industry 
Papaioannou 2011 Yes Yes Unrestricted grant from industry 
Rastelli 2011  No Yes Industry 
Steffensen 2011  Yes No Non-industry, drugs from industry 
Verschueren 2011  Yes No Non-industry 
Glendenning 2012 Yes No Non-industry 
Grimnes 2012  Yes No Non-industry, drugs from industry 
Nieves 2012  Yes No Non-industry 
Iuliano-Burns 2012 Yes No Non-industry 
Bolland 2013 Yes No Non-industry 
MacDonald 2013/Wood 2014 Yes No Non-industry 
Punthakee 2013 Yes Yes Industry 
Wamberg 2013 Yes No Not stated 
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Witham 2013 Yes No Non-industry 
Breslavsky 2014 Yes No Not stated 
Massart 2014 Yes Yes Industry funded 
Norenstedt 2014 Yes No Industry and non-industry funding, drugs from industry 
Rizzoli 2014 Yes Yes Industry funded 
Rolighed 2014 Yes No Non-industry 
Baron 2015 Yes Yes Non-industry, drugs from industry 
Cangussu 2015 Yes No Non-industry 
Hansen 2015 Yes Yes Non-industry 
Houston 2015 Yes No Non-industry 
Liyanage 2015 Yes No Non-industry 
Uusi-Rasi 2015 Yes No Non-industry 
Aspray 2016 Yes Yes Not stated 
Bischoff-Ferrari 2016 Yes Yes Mixed industry/ non-industry 
Jin 2016 Yes No Non-industry 
Mak 2016 Yes Yes Non-industry 
Mason 2016 Yes No Non-industry 
Aloia 2017 Yes No Not stated 
Eckard 2017 Yes Yes Non-industry 
Ginde 2017 Yes No Non-industry 
Hin 2017 Yes No Non-industry, drugs from industry 
Khaw 2017 Yes No Non-industry 
Larsen 2017 Yes No Non-industry 
Levis 2017 Yes No Non-industry 
Pop 2017 Yes No Non-industry 
Rahme 2017 Yes No Non-industry, drugs from industry 
Reid 2017 Yes No Non-industry 
Schwetz 2017 Yes Yes Industry and non-industry funding, drugs from industry 
Smith 2017 Yes No Non-industry 
Havens 2018 Yes No Non-industry 
Zheng 2018 Yes No Non-industry 
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e8: Table Outcome data by study 
Falls, hip fracture and Total fracture    
 
 Falls Hip fracture Total fracture 
  
Vit D or  
Higher dose 
Controls or 
 lower dose 
Vit D or  
Higher dose 
Controls or 
 lower dose 
Vit D or  
Higher dose 
Controls or 
 lower dose 
Study Treatment arm n N n N n N n N n N n N 
Graafmans 1996  62 177 65 177 
        Lips 1996  
    
58 1291 48 1287 135 1291 122 1287 
Komulainen 1998  
    
1 232 2 232 18 232 21 232 
 Vit D vs P 
    
1 116 2 116 11 116 15 116 
 Vit D/HRT vs HRT 
    
0 116 0 116 7 116 6 116 
Pfeifer 2000  11 74 19 74 0 74 1 74 3 74 6 74 
Meyer 2002  
    
50 569 47 575 69 569 76 575 
Bischoff 2003  14 62 18 60 2 62 1 60 
    Latham 2003  64 121 60 122 
        Trivedi 2003  254 1027 261 1011 21 1345 24 1341 119 1345 149 1341 
Avenell 2004   
    
1 70 3 64 6 70 11 64 
 Vit D vs Controls 
    
0 35 1 35 3 35 5 35 
 CaD vs Ca 
    
1 35 2 29 3 35 6 29 
Dhesi 2004  11 70 14 69 
        Harwood 2004  2 38 13 37 0 38 1 37 0 38 5 37 
Flicker 2005  170 313 185 312 
    
25 313 35 312 
Grant 2005  380 2649 381 2643 93 2649 90 2643 387 2649 377 2643 
 Vit D vs P 161 1306 185 1311 47 2649 41 2643 208 1343 192 1332 
 CaD vs Ca 219 1343 196 1332 46 2649 49 2643 179 1306 185 1311 
Bunout 2006  15 48 16 48 
         CaD vs Ca 6 24 11 24 
         CaD/ex vs Ca/ex 9 24 5 24 
        Law 2006 Cluster-adjusted 492 1127 533 1250 18 1326 15 1471 48 1326 38 1471 
 
Raw data 770 1762 833 1955 24 1762 20 1955 64 1762 51 1955 
Broe 2007  50 99 11 25 
        Burleigh 2007  36 101 45 104 1 101 2 104 1 101 3 104 
Lyons 2007  
    
112 1725 104 1715 205 1725 218 1715 
Smith 2007  2544 4727 2577 4713 66 4727 44 4713 306 4727 279 4713 
Prince 2008  80 151 95 151 
    
4 151 3 151 
Bischoff-Ferrari 2010  45 86 47 87 3 86 6 87 7 86 15 87 
Janssen 2010  
    
1 36 0 34 1 36 0 34 
Sanders 2010  837 1131 769 1125 19 1131 15 1125 155 1131 125 1125 
Witham 2010  2 53 5 52 0 53 0 52 2 53 1 52 
Mitri 2011  
        
1 86 0 86 
 Vit D vs P 
        
1 43 0 43 
 CaD vs Ca 
        
0 43 0 43 
Papaioannou 2011  
    
0 44 1 21 
    Steffensen 2011   
    
0 30 0 30 0 30 0 30 
Glendenning 2012  102 353 89 333 
    
10 353 10 333 
Grimnes 2012   
        
6 149 6 148 
Bolland 2013  
    
0 13 0 14 0 13 0 14 
MacDonald 2013  60 203 31 102 0 203 0 203 3 203 3 102 
 High vs Low dose 27 101 33 102 
    
0 101 3 102 
 High vs P 27 101 31 102 
    
0 101 3 102 
 Low vs P 33 102 31 102 
    
3 102 3 102 
Punthakee 2013  
        
3 607 3 614 
Witham 2013  25 80 26 79 
    
2 80 3 79 
Breslavsky 2014  
    
0 24 1 23 0 24 2 23 
Massart 2014  0 26 5 29 
    
0 26 5 29 
Rizzoli 2014  65 413 21 105 
        Baron 2015  
        
55 1130 64 1129 
Cangussu 2015  19 80 37 80 0 80 0 80 0 80 0 80 
Hansen 2015  46 154 23 76 
    
4 154 4 76 
 High vs Low dose 22 79 24 75 
    
2 79 2 75 
 High vs P 22 79 23 76 
    
2 79 4 76 
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 Low vs P 24 75 23 76 
    
2 75 4 76 
Houston 2015 Cluster-adjusted 11 37 12 29 
        
 
Raw data 11 38 12 30 
        Uusi-Rasi 2015  136 204 145 205 2 204 0 205 9 204 11 205 
 Vit D vs P 66 102 75 102 2 102 0 102 6 102 6 102 
 Vit D/ex vs P/ex 70 102 70 103 0 102 0 103 3 102 5 103 
Bischoff-Ferrari 2016  45 67 32 67 
        Jin 2016  2 209 0 204 
        Mak 2016  7 111 23 107 
    
3 111 3 107 
Aloia 2017  51 130 50 130 
        Ginde 2017  20 55 15 52 
    
4 55 8 52 
Hin 2017  34 204 14 101 
    
6 204 1 101 
Khaw 2017  1312 2558 1326 2552 9 2558 8 2552 156 2558 136 2552 
Larsen 2017  
    
0 256 0 255 15 256 13 255 
Levis 2017  8 66 11 64 0 66 0 64 0 66 0 64 
Schwetz 2017  27 249 33 243 
    
2 249 2 243 
Smith 2017  78 235 15 38 0 235 0 38 5 235 1 38 
 High vs Low dose 51 168 27 67 0 168 0 67 5 168 0 67 
 High vs P 51 168 15 38 0 168 0 38 5 168 1 38 
 Low vs P 27 67 15 38 0 67 0 38 0 67 1 38 
            
Bone density outcomes            
   
Vit D or 
Higher dose 
Controls or 
lower dose 
Between-group 
difference 
Study Treatment arm Site/Year Mean SD N Mean SD N Mean SE N1 N2 
Dawson-Hughes 1991  LS1 
      
0.70 0.34 110 110 
  TB1 
      
0.11 0.16 125 125 
Dawson-Hughes 1995  LS1 
      
-0.34 0.40 110 105 
  FN1 
      
0.98 0.42 121 122 
  TB1 
      
0.30 0.17 124 124 
  LS2 
      
-0.21 0.41 110 105 
  FN2 
      
1.48 0.50 121 122 
  TB2 
      
0.16 0.20 124 122 
Ooms 1995  FN1 
      
1.80 0.61 135 148 
  FR1 
      
-2.40 1.61 135 148 
  FN2 
      
1.90 0.77 118 126 
  FR2 
      
-0.30 2.35 118 126 
Komulainen 1999  LS3 -1.84 5.64 221 -2.17 5.28 226 
      FN3 -2.75 5.12 223 -2.85 5.04 228 
     Vit D/HRT vs HRT LS3 0.90 6.18 111 0.20 5.67 112 
      FN3 -1.30 5.20 115 -1.40 5.18 114 
     Vit D vs P LS3 -4.60 5.08 110 -4.50 4.90 114 
      FN3 -4.30 5.04 108 -4.30 4.90 114 
    Hunter 2000   LS1 1.11 3.08 64 1.06 3.19 64 
      TH1 -1.14 2.24 64 -1.13 2.28 64 
      FN1 0.22 3.08 64 -0.40 3.17 64 
      FR1 -0.96 2.84 64 -0.88 3.43 64 
      TB1 -0.27 2.33 64 -0.29 2.12 64 
      LS2 
      
-0.10 0.90 64 64 
  TH2 
      
0.70 0.63 64 64 
  FN2 
      
0.50 0.79 64 64 
  FR2 
      
-0.70 0.51 64 64 
  TB2 
      
0.20 0.57 64 64 
Patel 2001   LS1 
      
-0.56 0.37 35 35 
  TH1 
      
-0.07 0.36 35 35 
  FN1 
      
0.64 0.63 35 35 
  TB1 
      
-0.59 0.30 35 35 
Cooper 2003   LS1 -0.19 4.13 74 0.44 4.20 84 
      FN1 -1.81 3.90 74 -0.40 3.72 84 
      FR1 -1.69 2.53 74 -0.69 3.60 84 
      LS2 0.30 4.98 73 0.48 4.70 80 
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  FN2 0.52 4.28 73 1.18 4.12 80 
      FR2 -1.72 4.28 73 -1.46 4.12 80 
    Harwood 2004  LS1 -1.05 3.08 28 0.35 3.19 22 
      TH1 
      
2.00 0.79 22 28 
  FN1 
      
1.07 1.09 22 28 
Aloia 2005   LS1 0.67 3.40 104 0.52 2.44 104 
      TH1 1.10 2.09 104 1.03 2.30 104 
      FR1 1.60 3.15 104 1.16 4.02 104 
      TB1 1.49 3.79 104 1.54 2.83 104 
      LS2 0.81 3.04 104 0.75 3.44 104 
      TH2 -0.03 2.62 104 -0.24 2.48 104 
      FR2 -1.08 3.15 104 -0.50 2.99 104 
      TB2 -1.13 2.59 104 -1.29 3.29 104 
      LS3 0.25 1.82 104 0.30 1.82 104 
      TH3 -0.40 1.20 104 -0.40 1.80 104 
      FR3 -0.80 1.30 104 -0.55 1.80 104 
      TB3 -0.35 1.60 104 -0.30 1.50 104 
    Wissing 2005  LS1 -3.44 7.08 38 -1.42 8.12 41 
      FN1 -1.56 8.05 38 1.02 7.82 41 
    Bunout 2006  LS1 1.61 4.07 46 1.17 4.07 46 
      FN1 1.14 3.80 46 -1.08 3.73 46 
    Mikati 2006  LS1 1.13 2.70 36 0.65 3.19 36 
      TH1 0.81 1.96 36 0.62 2.23 36 
      FN1 -0.71 3.82 36 -0.92 3.98 36 
      FR1 0.78 2.14 36 0.89 3.06 36 
    Zhu 2008a  TH1 0.50 3.33 123 0.20 2.31 133 
      TB1 0.40 2.22 123 0.40 2.31 133 
    Zhu 2008b  TH1 -0.17 2.71 34 0.20 1.68 37 
      TH3 -0.39 4.32 34 -1.53 3.87 29 
    Andersen 2008   LS1 2.77 3.08 87 2.13 3.19 37 
      TB1 0.17 2.33 84 2.21 2.12 37 
     High vs Low dose LS1 4.85 3.08 47 0.85 3.19 40 
      TB1 -0.86 2.33 45 1.38 2.12 39 
    Islam 2010   LS1 1.45 4.01 40 -0.34 5.50 35 
      FN1 1.50 3.50 40 -1.30 1.56 35 
    Jorde 2010   LS1 0.64 2.99 207 0.56 3.36 105 
      TH1 0.87 1.29 207 0.82 1.56 105 
     High vs Low dose LS1 0.63 2.83 110 0.65 3.16 97 
      TH1 0.72 1.26 110 1.03 1.31 97 
    Rastelli 2011   LS1 0.12 3.76 21 -0.36 3.82 26 
      TH1 -0.01 3.16 21 0.04 3.21 26 
      FN1 0.45 3.30 21 -1.39 3.37 26 
    Steffensen 2011   LS2 
      
-0.20 0.77 33 35 
  TH2 
      
0.70 0.66 33 35 
  FR2 
      
1.00 1.40 33 35 
Verschueren 2011   TH1 
      
-0.08 0.44 56 55 
Grimnes 2012   LS1 0.25 3.19 149 0.32 3.23 148 
      TH1 0.31 1.59 149 0.56 1.70 148 
      FN1 0.03 2.08 149 0.17 1.87 148 
      TB1 0.18 1.14 149 0.20 1.23 148 
    Iuliano-Burns 2012  LS1 -0.76 3.76 71 -1.40 3.60 31 
      TH1 -0.16 2.85 71 -0.10 2.80 31 
      FN1 -0.36 3.99 71 0.40 3.70 31 
    Nieves 2012   LS2 -0.48 2.57 55 -0.59 2.40 48 
      TH2 -0.50 1.52 55 -0.69 1.46 48 
      FN2 -0.19 1.90 55 -0.80 1.80 48 
    Bolland 2013  LS1 0.03 2.55 13 0.06 2.11 13 
      TH1 -0.53 2.04 13 -0.78 2.43 13 
      FN1 0.37 1.80 13 -0.93 2.05 13 
      TB1 -0.62 0.94 13 -0.79 2.00 12 
    MacDonald 2013  LS1 0.01 2.79 171 -0.46 2.79 88 
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  TH1 -0.30 1.40 171 -0.60 1.66 88 
     High vs Low dose LS1 0.23 2.88 88 -0.23 2.69 83 
      TH1 -0.05 1.46 88 -0.57 1.33 83 
     High vs P LS1 0.23 2.88 88 -0.46 2.79 88 
      TH1 -0.05 1.46 88 -0.60 1.66 88 
     Low vs P LS1 -0.23 2.69 83 -0.46 2.79 88 
      TH1 -0.57 1.33 83 -0.60 1.66 88 
    Wamberg 2013  LS1 0.92 1.97 22 0.10 1.89 21 
      TH1 -0.37 2.25 22 -0.32 1.55 21 
      FN1 0.34 2.99 22 -0.16 2.92 21 
      FR1 0.37 1.53 22 -0.02 1.19 21 
      TB1 0.41 2.12 22 -0.48 2.02 21 
    Norenstedt 2014  LS1 3.60 4.07 66 3.00 4.22 69 
      TH1 2.80 2.37 66 2.10 2.30 69 
      FN1 3.20 2.37 66 2.30 2.74 69 
      FR1 0.20 3.85 66 0.30 3.26 69 
    Rolighed 2014  LS1 3.30 4.56 20 1.90 4.30 20 
      TH1 2.80 2.28 20 1.50 4.68 20 
      FN1 2.20 2.85 20 0.10 4.34 20 
      FR1 -1.30 3.88 20 -1.00 4.22 20 
    Hansen 2015  LS1 -0.15 2.64 148 0.20 3.18 73 
      TH1 -0.35 2.64 148 -0.90 3.19 73 
      FN1 -0.60 0.67 148 -0.80 3.17 73 
      TB1 -0.45 2.64 148 -0.50 3.19 73 
     High vs Low dose LS1 -0.30 3.08 74 0.00 2.11 74 
      TH1 -0.20 3.09 74 -0.50 2.11 74 
      FN1 -0.30 3.08 74 -0.90 2.12 74 
      TB1 -0.40 3.08 74 -0.50 2.12 74 
     High vs P LS1 -0.30 3.08 74 0.20 3.18 73 
      TH1 -0.20 3.09 74 -0.90 3.19 73 
      FN1 -0.30 3.08 74 -0.80 3.17 73 
      TB1 -0.40 3.08 74 -0.50 3.19 73 
     Low vs P LS1 0.00 2.11 74 0.20 3.18 73 
      TH1 -0.50 2.11 74 -0.90 3.19 73 
      FN1 -0.90 2.12 74 -0.80 3.17 73 
      TB1 -0.50 2.12 74 -0.50 3.19 73 
    Liyanage 2015  LS1 1.78 3.08 41 -1.41 3.19 41 
      TH1 2.62 2.24 41 -0.58 2.28 41 
      FN1 2.05 3.08 41 -1.38 3.17 41 
      TB1 2.02 2.33 41 -0.67 2.12 41 
    Uusi-Rasi 2015  LS1 0.71 3.19 185 0.23 3.34 189 
      FN1 -0.35 2.96 183 -0.83 3.16 186 
      LS2 1.07 3.97 182 0.78 3.91 180 
      FN2 -1.01 3.37 179 -1.19 3.50 176 
     Vit D vs P LS1 0.94 3.41 89 0.23 3.19 97 
      FN1 -0.18 2.93 86 -1.33 2.82 94 
      LS2 1.27 4.30 87 1.01 4.03 93 
      FN2 -0.77 3.42 84 -1.34 3.36 89 
     Vit D/ex vs P/ex LS1 0.49 2.98 96 0.24 3.49 92 
      FN1 -0.51 2.99 97 -0.31 3.48 92 
      LS2 0.89 3.65 95 0.53 3.78 87 
      FN2 -1.23 3.32 95 -1.04 3.63 87 
    Aspray 2016  TH1 -0.20 2.53 230 0.07 2.43 113 
    Mason 2016  LS1 -1.28 3.08 90 0.02 3.19 92 
      FN1 -1.16 3.08 88 -1.18 3.17 92 
    Aloia 2017  TH3 -1.69 3.56 98 -2.47 2.90 93 
      FN3 -1.28 4.65 98 -2.01 4.80 93 
      FR3 -1.68 3.08 98 -1.50 3.49 93 
    Eckard 2017  LS1 2.80 5.36 51 1.40 3.78 30 
      TH1 0.93 2.89 51 0.61 3.48 30 
    Larsen 2017  TH3 -0.52 2.74 201 -0.89 2.88 213 
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  FN3 -0.70 3.26 201 -1.28 3.26 213 
    Pop 2017  LS1 -0.40 3.08 39 -0.88 3.19 19 
      TH1 0.52 2.24 39 0.00 2.28 19 
      FN1 0.00 3.08 39 -2.22 3.17 19 
      FR1 0.00 2.84 39 0.00 3.43 19 
      TB1 0.43 2.33 39 0.00 2.12 19 
    Rahme 2017  LS1 1.65 3.21 110 1.34 3.42 112 
      TH1 0.47 2.22 110 0.50 2.26 112 
      FN1 0.66 4.16 110 0.55 3.78 112 
      TB1 1.18 4.13 110 0.19 2.66 112 
    Reid 2017  LS2 -0.06 3.57 228 -0.64 3.61 224 
      TH2 -0.71 2.43 228 -1.34 2.44 224 
      FN2 -0.55 2.97 228 -1.20 2.99 224 
      TB2 -0.70 1.66 228 -0.70 1.68 224 
    Havens 2018  LS1 1.15 2.59 99 0.09 3.01 89 
      TH1 -0.17 2.85 99 -0.42 1.76 89 
      TB1 0.00 2.33 99 -0.27 1.90 89 
    Zheng 2018  LS1 5.49 3.08 27 5.62 3.19 28 
      FN1 17.54 3.08 27 6.90 3.17 28 
     
Vit D- vitamin D; HRT- hormone replacement therapy; CaD- coadministered calcium and vitamin D; Ca- 
calcium; P-placebo; Ex- exercise; LS- lumbar spine; TH- total hip; FN- femoral neck; FR- forearm; TB- total 
body
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e9. Table: Analyses by population, duration of trial, and study design for bone density outcomes. 
 
Compare trials with missing measures of spread 
       Site Factors Population Design Group N, mean (95%CI) Group N, mean (95%CI) Group N, mean (95%CI) Pa 
Lumbar spine Year 1 Unselected Vit D vs Control Spread present 11, 0.20 (-0.12, 0.52) Spread absent 5, 0.24 (-1.31, 1.78) 
  
0.96 
Total hip Year 1 Unselected Vit D vs Control Spread present 9, 0.17 (-0.05, 0.39) Spread absent 2, 1.58 (-1.57, 4.73) 
  
0.38 
Femoral neck Year 1 Unselected Vit D vs Control Spread present 9, 0.86 (0.11, 1.60) Spread absent 3, 1.30 (-0.57, 3.17) 
  
0.66 
Forearm Year 1 Unselected Vit D vs Control Spread present 4, -0.21 (-1.14, 0.72) Spread absent 1, -0.08 (-1.17, 1.01) 
  
0.86 
Total body Year 1 Unselected Vit D vs Control Spread present 6, -0.02 (-0.30, 0.26) Spread absent 3, 0.22 (-2.30, 2.74) 
  
0.86 
           Lumbar spine Year 1 Unselected High vs low dose Spread present 4, -0.01 (-0.44, 0.43) Spread absent 1, 0.48 (-1.23, 2.19) 
  
0.59 
Total hip Year 1 Unselected High vs low dose Spread present 5, -0.19 (-0.44, 0.07) Spread absent 1, 0.52 (-0.71, 1.76) 
  
0.27 
Femoral neck Year 1 Unselected High vs low dose Spread present 4, 0.15 (-0.50, 0.79) Spread absent 1, 2.22 (0.52, 3.93) 
  
0.03 
Total body Year 1 Unselected High vs low dose Spread present 3, 0.26 (-0.15, 0.66) Spread absent 1, 0.43 (-0.81, 1.67) 
  
0.79 
           Lumbar spine Year 1 Selected Vit D vs Control Spread present 4, 0.30 (-0.69, 1.28) Spread absent 1, -0.12 (-1.78, 1.54) 
  
0.67 
Femoral neck Year 1 Selected Vit D vs Control Spread present 4, 0.92 (-0.18, 2.03) Spread absent 1, 10.65 (9.00, 12.30) 
  
<0.01 
           Compare results by year for each population type and study design for dose 
     Lumbar spine 
 
Unselected Vit D vs Control Year 1 16, 0.22 (-0.21, 0.65) Year 2 6, 0.27 (-0.11, 0.65) Year 3+ 2, 0.02 (-0.42, 0.47) 0.70 
Lumbar spine 
 
Unselected High vs low dose Year 1 5, 0.02 (-0.40, 0.45) Year 2 1, -0.21 (-1.01, 0.59) 
  
0.61 
Lumbar spine 
 
Selected Vit D vs Control Year 1 5, 0.19 (-0.66, 1.03) Year 2 1, -0.20 (-1.70, 1.30) 
  
0.66 
Total hip 
 
Unselected Vit D vs Control Year 1 11, 0.44 (0.01, 0.88) Year 2 5, 0.43 (0.13, 0.74) Year 3+ 1, 0.27 (-0.09, 0.62) 0.75 
Total hip 
 
Selected Vit D vs Control Year 1 3, 0.68 (0.00, 1.37) Year 2 1, 0.70 (-0.60, 2.00) 
  
0.98 
Femoral neck 
 
Unselected Vit D vs Control Year 1 12, 0.96 (0.29, 1.63) Year 2 6, 0.49 (0.04, 0.94) Year 3+ 3, 0.47 (-0.02, 0.95) 0.45 
Femoral neck 
 
Unselected High vs low dose Year 1 5, 0.40 (-0.38, 1.17) Year 2 1, 1.48 (0.50, 2.46) 
  
0.09 
Forearm 
 
Unselected Vit D vs Control Year 1 5, -0.15 (-0.85, 0.55) Year 2 4, -0.55 (-1.13, 0.02) Year 3+ 2, -0.24 (-0.63, 0.15) 0.60 
Forearm 
 
Selected Vit D vs Control Year 1 2, -0.14 (-1.22, 0.95) Year 2 1, 1.00 (-1.75, 3.75) 
  
0.45 
Total body 
 
Unselected Vit D vs Control Year 1 9, 0.08 (-0.53, 0.69) Year 2 3, 0.04 (-0.24, 0.32) Year 3+ 1, -0.05 (-0.47, 0.37) 0.92 
Total body 
 
Unselected High vs low dose Year 1 4, 0.25 (-0.10, 0.60) Year 2 1, 0.16 (-0.23, 0.55) 
  
0.74 
           Compare results by population type and study design for dose for each year 
     Lumbar spine Year 1 Unselected Vit D vs Control 
 
16, 0.22 (-0.21, 0.65) 
    
0.14 
  
Unselected High vs low dose 
 
5, 0.02 (-0.40, 0.45) 
     
  
Selected Vit D vs Control 
 
5, 0.19 (-0.66, 1.03) 
     
  
Selected High vs low dose 
 
4, 0.92 (0.29, 1.55) 
     
 
Year 2 Unselected Vit D vs Control 
 
6, 0.27 (-0.11, 0.65) 
    
0.51 
  
Unselected Vit D vs Control 
 
1, -0.21 (-1.01, 0.59) 
     
  
Selected Vit D vs Control 
 
1, -0.20 (-1.70, 1.30) 
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Total hip Year 1 Unselected Vit D vs Control 
 
11, 0.44 (0.01, 0.88) 
    
0.02 
  
Unselected High vs low dose 
 
6, -0.16 (-0.41, 0.09) 
     
  
Selected Vit D vs Control 
 
3, 0.68 (0.00, 1.37) 
     
  
Selected High vs low dose 
 
4, 0.22 (-0.28, 0.72) 
     
 
Year 2 Unselected Vit D vs Control 
 
4, 0.43 (0.13, 0.74) 
    
0.69 
  
Selected Vit D vs Control 
 
1, 0.70 (-0.60, 2.00) 
     Femoral neck Year 1 Unselected Vit D vs Control 
 
12, 0.96 (0.29, 1.63) 
    
0.55 
  
Unselected High vs low dose 
 
5, 0.40 (-0.38, 1.17) 
     
  
Selected Vit D vs Control 
 
5, 2.58 (-1.37, 6.53) 
     
  
Selected High vs low dose 
 
2, 0.99 (-0.59, 2.58) 
     
 
Year 2 Unselected Vit D vs Control 
 
6, 0.49 (0.04, 0.94) 
    
0.07 
  
Unselected High vs low dose 
 
1, 1.48 (0.50, 2.46) 
     Forearm Year 1 Unselected Vit D vs Control 
 
5, -0.15 (-0.85, 0.55) 
    
>0.99 
  
Unselected High vs low dose 
 
1, 0.00 (-1.67, 1.67) 
     
  
Selected Vit D vs Control 
 
2, -0.14 (-1.22, 0.95) 
     
  
Selected High vs low dose 
 
1, -0.12 (-1.34, 1.10) 
     
 
Year 2 Unselected Vit D vs Control 
 
4, -0.55 (-1.13, 0.02) 
    
0.28 
  
Selected Vit D vs Control 
 
1, 1.00 (-1.75, 3.75) 
     Total body Year 1 Unselected Vit D vs Control 
 
9, 0.08 (-0.53, 0.69) 
    
0.97 
  
Unselected High vs low dose 
 
4, 0.25 (-0.10, 0.60) 
     
  
Selected Vit D vs Control 
 
1, 0.17 (-1.04, 1.38) 
     
  
Selected High vs low dose 
 
1, 0.27 (-0.34, 0.88) 
     
 
Year 2 Unselected Vit D vs Control 
 
3, 0.04 (-0.24, 0.32) 
    
0.24 
  
Selected Vit D vs Control 
 
1, 0.16 (-0.23, 0.55) 
     
           Compare results by year, pooling studies by population type and study design for dose 
     Lumbar spine 
   
Year 1 30, 0.25 (-0.04, 0.54) Year 2 8, 0.16 (-0.17, 0.50) Year 3+ 2, 0.02 (-0.42, 0.47) 0.71 
Total hip 
   
Year 1 24, 0.26 (0.01, 0.51) Year 2 5, 0.45 (0.15, 0.74) Year 3+ 4, 0.27 (-0.09, 0.62) 0.60 
Femoral neck 
   
Year 1 24, 1.23 (0.12, 0.54) Year 2 7, 0.63 (0.06, 0.16) Year 3+ 3, 0.47 (0.06, -0.02) 0.20 
Forearm 
   
Year 1 9, -0.08 (-0.48, 0.32) Year 2 5, -0.49 (-1.05, 0.07) Year 3+ 2, -0.24 (-0.63, 0.15) 0.50 
Total body 
   
Year 1 15, 0.16 (-0.18, 0.50) Year 2 4, 0.08 (-0.15, 0.31) Year 3+ 1, -0.05 (-0.47, 0.37) 0.75 
           Femoral neck, Zheng 2018 excluded 
 
Year 1 23, 0.81 (0.37, 1.25) Year 2 7, 0.63 (0.16, 1.10) Year 3+ 3, 0.47 (-0.02, 0.95) 0.59 
           Compare results by site using final time point results only from each study 
     Lumbar spine 
    
34, 0.25 (0.00, 0.49) 
     Total hip 
    
29, 0.34 (0.13, 0.55) 
     Femoral neck 
    
29, 1.12 (0.58, 1.65) 
     Forearm 
    
11, -0.16 (-0.46, 0.13) 
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Total body 
    
16, 0.13 (-0.16, 0.42) 
     
           Femoral neck, Zheng 2018 excluded 
  
28, 0.76 (0.42, 1.09) 
      
N- number of studies; mean- weighted mean between-group difference in bone mineral density; Vit D- vitamin D;. 
a P values are for the test of interaction between subgroups. 
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e10. Figure: Forearm bone density 
 
 
The top panel shows random effects meta-analyses of vitamin D supplementation on forearm bone mineral 
density (BMD) by trial duration and the pooled analysis of all trials using the final time point. The bottom panel 
shows trial sequential analysis of all trials of vitamin D on forearm BMD for a mean difference of 0.5% (see 
Figure 1 for detailed description). 
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e11. Figure: Total body bone density 
 
 
The top panel shows random effects meta-analyses of vitamin D supplementation on total body bone mineral 
density (BMD) by trial duration and the pooled analysis of all trials using the final time point. The bottom panel 
shows the trial sequential analysis of all trials of vitamin D on total body BMD (see Figure 1 for description). 
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e12. Table: Reported subgroup analyses based on baseline 25-hydroxyvitamin D 
 
 
Fracture Falls Bone density 
 
Threshold 
(nmol/L) Result 
Comparison 
to primary 
analysis 
Threshold 
(nmol/L) Result 
Comparison 
to primary 
analysis 
Threshold 
(nmol/L) Result 
Comparison 
to primary 
analysis 
Patel 2001  
      
<60 only No effect 
Similar to 
primary 
Latham 2003 
   
<25 No effect 
Similar to 
primary    
Harwood 2004 
<30 (and PTH 
<50) only No effect 
Similar to 
primary 
<30 (and PTH 
<50) only No effect 
Similar to 
primary 
<30 (and PTH 
<50) only Mixed 
Similar to 
primary 
Aloia 2005  
      
Not stated No effect 
Similar to 
primary 
Zhu 2008b 
      
<68, >68 Positive Mixed 
Jorde 2010  
      
<45 only No effect 
Similar to 
primary 
Grimnes 2012  
      
<69.7, >69.7  
<55, >55 
No 
interaction 
Similar to 
primary 
MacDonald 2013 
      
<50 only Mixed 
Similar to 
primary 
Norenstedt 2014 
      
<50 or >50 No effect 
Similar to 
primary 
Bischoff-Ferrari 2016 
   
<50, >50 Mixed 
Similar to 
primary    
Mason 2016 
      
<50 only Mixed Mixed 
Ginde 2017 
   
<50, >50 No interaction 
Similar to 
primary    
Khaw 2017 
<50; <25, 25-50, 
50-75 vs 75+ No effect 
Similar to 
primary <50 only No effect 
Similar to 
primary    
Larsen 2017 
      
<50 only No effect 
Similar to 
primary 
Rahme 2017 
      
<50, >50 and 
PTH <76 Mixed Mixed 
Reid 2017 
      
<25, >25; 
<30, >30;  
<40, >40; 
<50, >50 Mixed 
Similar to 
primary 
Schwetz 2017 <25, >25 No effect 
Similar to 
primary <25, >25 No effect 
Similar to 
primary <25 or >25 
No 
difference 
Similar to 
primary 
Havens 2018 
      
<50 or >50 
only in vit D 
group  
No 
difference 
Similar to 
primary 
 
25OHD- 25 hydroxyvitamin D; PTH- parathyroid hormone; Vit D- vitamin D; 
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e13. Table: Results of subgroups analyses for falls and fracture 
 
Subgroups Group N, RR, 95% CI Group N, RR, 95% CI Group N, RR, 95% CI Pa 
Total fracture        
Age <65 years 7, 0.88 (0.67, 1.14) 65+ years 29, 1.00 (0.92, 1.09) 
  
0.34 
BMI <30 kg/m2 26, 0.95 (0.87, 1.03) 30+ kg/m2 4, 0.78 (0.32, 1.90) 
  
0.66 
Duration ≤12 m 22, 0.92 (0.71, 1.19) >12 m 14, 1.00 (0.92, 1.09) 
  
0.52 
Trial size ≤200 12, 0.50 (0.32, 0.77) >200 24, 1.02 (0.96, 1.09) 
  
0.002 
Site 
Community-
dwelling 28, 1.01 (0.93, 1.09) Residential Care 8, 0.98 (0.84, 1.14) 
  
0.73 
Risk of bias Low 9, 1.00 (0.90, 1.11) Moderate/High 27, 0.99 (0.88, 1.10) 
  
0.85 
Vit D Dose >800 IU/d 18, 1.07 (0.94, 1.22) ≤800 IU/d 17, 0.98 (0.90, 1.08) 
  
0.29 
Dose Frequency Daily 19, 0.97 (0.88, 1.07) Intermittent 16, 1.03 (0.92, 1.16) Mixed 1, 0.49 (0.13, 1.92) 0.43 
Coadministered 
therapy No 25, 1.04 (0.97, 1.12) Yes 11, 0.89 (0.77, 1.04) 
  
0.07 
 Therapy   Calcium 9, 0.89 (0.77, 1.04) 
  
0.76 
 
  Calcium/Exercise 1, 0.61 (0.15, 2.47) 
   
 
  Exercise 1, 1.17 (0.40, 3.37) 
   
Baseline 25OHD <25 nmol/L 2, 0.79 (0.14, 4.33) 25+ nmol/L 29, 1.05 (0.98, 1.13) 
  
0.74 
 
<50 nmol/L 18, 1.03 (0.93, 1.14) 50+ nmol/L 13, 1.08 (0.97, 1.21) 
  
0.52 
 
<75 nmol/L 31, 1.05 (0.98, 1.14) 75+ nmol/L - 
   
Achieved 25OHD <50 nmol/L 5, 0.70 (0.36, 1.35) 50+ nmol/L 27, 1.02 (0.95, 1.09) 
  
0.27 
 
<75 nmol/L 16, 1.03 (0.93, 1.14) 75+ nmol/L 16, 0.96 (0.85, 1.09) 
  
0.42 
High vs low dose 
within study 
 
7, 0.65 (0.39, 1.07) 
     
        
Hip fracture        
Age <65 years 1, 0.50 (0.05, 5.48) 65+ years 19, 1.11 (0.97, 1.26) 
  
0.51 
BMI <30 kg/m2 14, 0.99 (0.81, 1.22) 
     
Duration ≤12 m 9, 0.95 (0.56, 1.62) >12 m 11, 1.12 (0.98, 1.28) 
  
0.57 
Trial size ≤200 9, 0.53 (0.24, 1.16) >200 11, 1.13 (0.99, 1.29) 
  
0.06 
Site 
Community-
dwelling 13, 1.09 (0.90, 1.32) Residential Care 7, 1.12 (0.94, 1.34) 
  
0.84 
Risk Low 7, 1.12 (0.98, 1.29) Moderate/High 13, 0.96 (0.62, 1.49) 
  
0.50 
Vit D Dose >800 IU/d 3, 1.17 (0.68, 2.00) ≤800 IU/d 15, 1.11 (0.97, 1.28) 
  
0.88 
Dose Frequency Daily 12, 1.06 (0.87, 1.28) Intermittent 8, 1.15 (0.96, 1.38) 
  
0.51 
Coadministered 
therapy No 13, 1.15 (1.00, 1.32) Yes 7, 0.91 (0.63, 1.32) 
  
0.24 
 Therapy   Calcium 7, 0.91 (0.63, 1.32) 
   
Baseline 25OHD <25 nmol/L 1, 0.51 (0.05, 5.59) 25+ nmol/L 16, 1.15 (0.98, 1.35) 
  
0.51 
 
<50 nmol/L 13, 1.06 (0.89, 1.27) 50+ nmol/L 4, 1.43 (1.05, 1.96) 
  
0.10 
 
<75 nmol/L 17, 1.15 (0.98, 1.34) 75+ nmol/L - 
   
Achieved 25OHD <50 nmol/L 4, 0.43 (0.11, 1.66) 50+ nmol/L 15, 1.12 (0.98, 1.28) 
  
0.17 
 
<75 nmol/L 13, 1.14 (0.97, 1.33) 75+ nmol/L 6, 1.05 (0.83, 1.34) 
  
0.61 
High vs low dose 
within study 
 
2, 0.42 (0.12, 1.47) 
     
        
Falls        
Age <65 years 4, 0.83 (0.55, 1.24) 65+ years 33, 0.98 (0.94, 1.02) 
  
0.42 
BMI <30 kg/m2 28, 0.95 (0.89, 1.02) 30+ kg/m2 3, 0.76 (0.52, 1.11) 
  
0.25 
Duration ≤12 m 28, 0.91 (0.83, 1.01) >12 m 9, 1.00 (0.96, 1.04) 
  
0.10 
Trial size ≤200 16, 0.84 (0.69, 1.03) >200 21, 0.99 (0.95, 1.03) 
  
0.12 
Site 
Community-
dwelling 30, 0.97 (0.92, 1.02) Residential Care 7, 0.98 (0.92, 1.05) 
  
0.74 
Risk Low 22, 0.99 (0.94, 1.04) Moderate/High 15, 0.90 (0.81, 1.00) 
  
0.12 
Vit D Dose >800 IU/d 21, 0.95 (0.89, 1.02) ≤800 IU/d 15, 0.98 (0.95, 1.01) 
  
0.45 
Dose Frequency Daily 18, 0.92 (0.87, 0.98) Intermittent 18, 1.01 (0.95, 1.07) Mixed 1, 0.99 (0.65, 1.50) 0.13 
Coadministered No 24, 0.98 (0.93, 1.03) Yes 12, 0.95 (0.87, 1.04) 
  
0.55 
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therapy 
 Therapy   Calcium 8, 0.92 (0.82, 1.03) 
  
0.25 
 
  Calcium/Exercise 1, 1.80 (0.71, 4.59) 
   
 
  Exercise 2, 1.03 (0.89, 1.20) 
   
 
  Strontium 1, 0.79 (0.51, 1.23) 
   
Baseline 25OHD <25 nmol/L 2, 0.80 (0.57, 1.11) 25+ nmol/L 31, 0.98 (0.93, 1.03) 
  
0.24 
 
<50 nmol/L 22, 0.92 (0.83, 1.02) 50+ nmol/L 11, 0.99 (0.94, 1.03) 
  
0.25 
 
<75 nmol/L 33, 0.97 (0.92, 1.03) 75+ nmol/L - 
   
Achieved 25OHD <50 nmol/L 4, 0.60 (0.33, 1.07) 50+ nmol/L 30, 0.99 (0.94, 1.03) 
  
0.10 
 
<75 nmol/L 19, 0.96 (0.91, 1.03) 75+ nmol/L 15, 0.99 (0.90, 1.10) 
  
0.66 
High vs low dose 
within study 
 
7, 0.90 (0.69, 1.18) 
      
N- number of studies; RR- relative risk; BMI- body mass index; vit D- vitamin D;  
25OHD- 25-hydroxyvitamin D  
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e14. Table: Results of subgroups analyses for bone density 
 
Subgroups Group N, mean, 95% CI Group N, mean, 95% CI Group N, mean, 95% CI P 
Lumbar spine        
Age <65 years 6, 0.30 (-0.11, 0.70) 65+ years 28, 0.27 (-0.03, 0.56) 
  
0.91 
BMI <30 kg/m2 25, 0.38 (0.07, 0.69) 30+ kg/m2 9, -0.05 (-0.41, 0.32) 
  
0.08 
Duration ≤12 m 24, 0.39 (0.03, 0.75) >12 m 10, 0.03 (-0.23, 0.29) 
  
0.11 
Trial size ≤200 21, 0.39 (-0.05, 0.83) >200 13, 0.16 (-0.13, 0.45) 
  
0.39 
Site 
Community-
dwelling 34, 0.25 (0.00, 0.49) Residential Care - 
   
Risk of bias Low 22, 0.35 (0.04, 0.67) Moderate/High 12, 0.03 (-0.35, 0.41) 
  
0.20 
Vit D Dose >800 IU/d 14, 0.30 (-0.21, 0.81) ≤800 IU/d 13, 0.10 (-0.21, 0.41) 
  
0.51 
Dose Frequency Daily 18, 0.15 (-0.13, 0.44) Intermittent 15, 0.42 (-0.05, 0.88) Mixed 1, -0.35 (-1.14, 0.44) 0.25 
Coadministered 
therapy No 14, 0.29 (-0.28, 0.85) Yes 12, 0.16 (-0.12, 0.44) 
  
0.70 
 Therapy   Calcium 9, 0.14 (-0.16, 0.43) 
  
0.87 
 
  Calcium/Cinacalcet 1, -0.12 (-1.78, 1.54) 
   
 
  Exercise 1, 0.36 (-0.72, 1.44) 
   
Baseline 25OHD <25 nmol/L 31, 0.23 (-0.04, 0.51) 25+ nmol/L 1, 0.64 (-0.56, 1.83) 
  
0.52 
 
<50 nmol/L 15, 0.34 (0.07, 0.61) 50+ nmol/L 17, 0.13 (-0.29, 0.56) 
  
0.42 
 
<75 nmol/L 1, -0.18 (-1.71, 1.35) 75+ nmol/L 31, 0.26 (-0.02, 0.53) 
  
0.58 
Achieved 25OHD <50 nmol/L 3, 0.05 (-0.97, 1.06) 50+ nmol/L 31, 0.26 (0.00, 0.52) 
  
0.69 
 
<75 nmol/L 12, 0.36 (-0.01, 0.73) 75+ nmol/L 22, 0.22 (-0.10, 0.54) 
  
0.58 
High vs low dose 
within study 
 
13, 0.57 (0.03, 1.11) 
     
        
Total hip        
Age <65 years 8, 0.34 (-0.06, 0.73) 65+ years 21, 0.34 (0.08, 0.60) 
  
0.97 
BMI <30 kg/m2 20, 0.45 (0.14, 0.76) 30+ kg/m2 8, 0.08 (-0.12, 0.29) 
  
0.05 
Duration ≤12 m 20, 0.35 (0.05, 0.65) >12 m 9, 0.32 (0.10, 0.53) 
  
0.87 
Trial size ≤200 17, 0.59 (0.15, 1.04) >200 12, 0.16 (-0.02, 0.34) 
  
0.08 
Site 
Community-
dwelling 28, 0.35 (0.14, 0.57) Residential Care 1, -0.08 (-0.93, 0.77) 
  
0.33 
Risk of bias Low 22, 0.31 (0.08, 0.55) Moderate/High 7, 0.43 (-0.05, 0.92) 
  
0.66 
Vit D Dose >800 IU/d 15, 0.62 (0.29, 0.96) ≤800 IU/d 6, 0.19 (-0.16, 0.55) 
  
0.09 
Dose Frequency Daily 13, 0.23 (0.04, 0.42) Intermittent 15, 0.42 (0.05, 0.80) Mixed 1, 0.55 (-0.25, 1.35) 0.54 
Coadministered 
therapy No 11, 0.74 (0.25, 1.22) Yes 8, 0.18 (-0.02, 0.39) 
  
0.04 
 Therapy   Calcium 8, 0.18 (-0.02, 0.39) 
   
Baseline 25OHD <25 nmol/L 28, 0.32 (0.11, 0.54) 25+ nmol/L - 
   
 
<50 nmol/L 12, 0.19 (0.00, 0.38) 50+ nmol/L 16, 0.43 (0.07, 0.79) 
  
0.25 
 
<75 nmol/L 28, 0.32 (0.11, 0.54) 75+ nmol/L - 
   
Achieved 25OHD <50 nmol/L 1, 2.00 (0.46, 3.55) 50+ nmol/L 28, 0.31 (0.10, 0.51) 
  
0.03 
 
<75 nmol/L 8, 0.34 (0.08, 0.59) 75+ nmol/L 21, 0.34 (0.07, 0.62) 
  
0.97 
High vs low dose 
within study 
 
13, -0.01 (-0.20, 0.18) 
     
        Femoral neck        
Age <65 years 7, 0.74 (0.23, 1.25) 65+ years 21, 0.75 (0.32, 1.17) 
  
0.98 
BMI <30 kg/m2 19, 0.79 (0.33, 1.25) 30+ kg/m2 8, 0.63 (0.13, 1.12) 
  
0.64 
Duration ≤12 m 17, 0.95 (0.38, 1.52) >12 m 11, 0.57 (0.27, 0.87) 
  
0.25 
Trial size ≤200 17, 1.08 (0.49, 1.67) >200 11, 0.39 (0.09, 0.69) 
  
0.04 
Site 
Community-
dwelling 28, 0.76 (0.42, 1.09) Residential Care - 
   
Risk of bias Low 18, 0.72 (0.31, 1.12) Moderate/High 10, 0.87 (0.30, 1.44) 
  
0.67 
Vit D Dose >800 IU/d 12, 0.76 (0.32, 1.20) ≤800 IU/d 10, 0.82 (0.11, 1.52) 
  
0.89 
Dose Frequency Daily 15, 0.88 (0.46, 1.29) Intermittent 12, 0.67 (0.06, 1.29) Mixed 1, 0.20 (-0.33, 0.73) 0.14 
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Coadministered 
therapy No 14, 1.02 (0.53, 1.50) Yes 8, 0.27 (-0.19, 0.72) 
  
0.03 
 Therapy   Calcium 6, 0.34 (-0.24, 0.93) 
  
0.66 
 
  Exercise 1, -0.19 (-1.20, 0.82) 
   
 
  HRT 1, 0.10 (-1.24, 1.44) 
   
Baseline 25OHD <25 nmol/L 25, 0.68 (0.33, 1.04) 25+ nmol/L 1, 1.90 (0.40, 3.40) 
  
0.12 
 
<50 nmol/L 10, 1.11 (0.55, 1.67) 50+ nmol/L 16, 0.50 (0.08, 0.92) 
  
0.09 
 
<75 nmol/L 1, -0.66 (-1.99, 0.67) 75+ nmol/L 25, 0.77 (0.42, 1.13) 
  
0.04 
Achieved 25OHD <50 nmol/L 2, 0.25 (-0.60, 1.11) 50+ nmol/L 26, 0.78 (0.43, 1.14) 
  
0.26 
 
<75 nmol/L 11, 0.95 (0.28, 1.61) 75+ nmol/L 17, 0.64 (0.26, 1.02) 
  
0.43 
High vs low dose 
within study 
 
8, 0.59 (-0.05, 1.23) 
     
        Forearm        
Age <65 years 2, -0.18 (-1.10, 0.73) 65+ years 9, -0.16 (-0.47, 0.15) 
  
0.96 
BMI <30 kg/m2 6, -0.28 (-0.84, 0.28) 30+ kg/m2 4, -0.11 (-0.48, 0.26) 
  
0.62 
Duration ≤12 m 5, 0.11 (-0.43, 0.66) >12 m 6, -0.27 (-0.62, 0.07) 
  
0.24 
Trial size ≤200 8, -0.06 (-0.51, 0.38) >200 3, -0.24 (-0.63, 0.15) 
  
0.56 
Site 
Community-
dwelling 11, -0.16 (-0.46, 0.13) Residential Care - 
   
Risk of bias Low 7, -0.12 (-0.44, 0.21) Moderate/High 4, -0.37 (-1.05, 0.30) 
  
0.50 
Vit D Dose >800 IU/d 6, 0.06 (-0.43, 0.55) ≤800 IU/d 3, -0.32 (-0.71, 0.07) 
  
0.24 
Dose Frequency Daily 8, -0.18 (-0.48, 0.13) Intermittent 3, -0.01 (-0.99, 0.96) 
  
0.75 
Coadministered 
therapy No 4, -0.06 (-0.68, 0.55) Yes 5, -0.21 (-0.56, 0.15) 
  
0.69 
 Therapy   Calcium 5, -0.21 (-0.56, 0.15) 
   
Baseline 25OHD <25 nmol/L 9, -0.16 (-0.47, 0.15) 25+ nmol/L 1, -0.30 (-4.90, 4.30) 
  
0.95 
 
<50 nmol/L 5, -0.11 (-0.46, 0.23) 50+ nmol/L 5, -0.34 (-1.02, 0.33) 
  
0.56 
 
<75 nmol/L 1, -0.26 (-1.59, 1.07) 75+ nmol/L 9, -0.16 (-0.47, 0.16) 
  
0.88 
Achieved 25OHD <50 nmol/L - 50+ nmol/L 11, -0.16 (-0.46, 0.13) 
   
 
<75 nmol/L 3, -0.11 (-0.96, 0.73) 75+ nmol/L 8, -0.17 (-0.48, 0.14) 
  
0.90 
High vs low dose 
within study 
 
 
     
        
Total body        
Age <65 years 3, 0.18 (-0.27, 0.63) 65+ years 13, 0.11 (-0.25, 0.48) 
  
0.82 
BMI <30 kg/m2 11, 0.05 (-0.31, 0.42) 30+ kg/m2 5, 0.30 (-0.14, 0.73) 
  
0.39 
Duration ≤12 m 11, 0.27 (-0.19, 0.73) >12 m 5, -0.03 (-0.25, 0.18) 
  
0.24 
Trial size ≤200 7, 0.23 (-0.91, 1.37) >200 9, 0.07 (-0.07, 0.20) 
  
0.78 
Site 
Community-
dwelling 16, 0.13 (-0.16, 0.42) Residential Care - 
   
Risk of bias Low 10, 0.21 (-0.23, 0.65) Moderate/High 6, 0.04 (-0.20, 0.28) 
  
0.50 
Vit D Dose >800 IU/d 6, 0.59 (-0.14, 1.32) ≤800 IU/d 6, -0.36 (-0.89, 0.17) 
  
0.04 
Dose Frequency Daily 8, -0.17 (-0.57, 0.23) Intermittent 7, 0.56 (0.03, 1.08) Mixed 1, 0.05 (-0.74, 0.84) 0.10 
Coadministered 
therapy No 8, 0.13 (-0.63, 0.90) Yes 3, 0.04 (-0.19, 0.27) 
  
0.82 
 Therapy   Calcium 3, 0.04 (-0.19, 0.27) 
   
Baseline 25OHD <25 nmol/L 1, -2.04 (-2.92, -1.16) 25+ nmol/L 13, 0.27 (-0.05, 0.59) 
 
 <0.01 
 
<50 nmol/L 6, -0.15 (-0.78, 0.47) 50+ nmol/L 8, 0.37 (-0.12, 0.87) 
  
0.20 
 
<75 nmol/L 14, 0.15 (-0.22, 0.51) 75+ nmol/L - 
   
Achieved 25OHD <50 nmol/L 1, -2.04 (-2.92, -1.16) 50+ nmol/L 15, 0.22 (-0.03, 0.47) 
  
<0.01 
 
<75 nmol/L 2, -0.99 (-2.99, 1.01) 75+ nmol/L 14, 0.24 (-0.03, 0.51) 
  
0.23 
High vs low dose 
within study 
 
7, -0.02 (-0.52, 0.47) 
      
N- number of studies; mean- weighted mean between group difference in bone density; BMI- body mass index; 
vit D- vitamin D; 25OHD- 25-hydroxyvitamin D. 
a P values are for the test of interaction between subgroups. 
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